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 ABSTRACT  
 
Aorta-derived mesoangioblasts (ADM) are multipotent adult stem cells that 
differentiate to adipocytes, smooth muscle cells, skeletal myotubes, oligodendrocyte 
precursors, and cardiomyocytes, indicating that they can be used for regeneration in 
severe disease in which multiple tissues are affected. Duchenne muscular dystrophy 
(DMD) is a fatal muscle-wasting disease, and patients with DMD do not survive beyond 
their early 30s. The most common causes of the death in DMD patients are cardiac and 
respiratory failure. Currently, there are advanced treatments and equipment for improving 
respiratory function so that it is possible to prolong the life of DMD patients. With 
increased lifespan dilated cardiomyopathy (DCM) has become prevalent in patients with 
DMD, and all patients develop DCM by 18 years of age about their mid-teen. However 
there have been not many studies that have focused on therapy for cardiomyopathy in 
DMD.  This project is focused on determining whether ADM ameliorate cardiomyopathy 
in murine models for DMD, mdx and mdx/utrn-/- mice, and whether ADM are good 
candidates for cell-based therapy of DCM in DMD.  
In the first part of study, mdx/utrn-/- mice were characterized to determine whether 
they develop DCM similar to patients with DMD as a good disease model of DMD.  
DCM was not observed in mdx/utrn-/- mice at 5 weeks of age. However cardiac function 
and ventricular wall thickness decreased continuously at 10 and 15 weeks of age and an 
increase in fibrosis in the left ventricular posterior wall was observed, similar to patients 
with DMD. In the second part of the study we examined whether ADM differentiate into 
cardiomyocytes to determine whether they were a good source for stem cell therapy in 
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DMD. ADM differentiated to cardiomyocytes that expressed of cardiac specific mRNAs 
and proteins in vitro and in vivo, and restored dystrophin in the heart of young mdx mice 
after intramyocardiac injection. In the last study ADM were transplanted into hearts of 
mdx and mdx/utrn-/- mice and the effect of ADM transplantation on DCM was examined. 
With ADM transplantation mdx/utrn-/- mice did not develop DCM in contrast to sham-
injected mice which exhibited decreased heart function. Increased angiogenesis and 
proliferation were detected in mdx/utrn-/- heart after ADM transplantation which may 
contribute to the positive effects of ADM in mdx/utrn-/- cardiac muscle. In addition 
restored dystrophin was detected in mdx/utrn-/- heart after ADM injection. However, no 
cardiac functional improvement or dystrophin protein was detected in mdx mice with 
ADM transplantation. 
To conclude development of DCM in mdx/utrn-/- mice was prevented or delayed 
by ADM transplantation correlating with angiogenesis and increased cell proliferation as 
well as restored dystrophin expression. ADM may therefore be a good stem cell source 
for treatment of DCM in DMD by preventing or delaying their development. However 
ADM are not a good stem cell source for treatment of pre-existing DCM at late disease 
stages.  
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Chapter I 
Introduction and literature review 
 
A. Duchenne muscular dystrophy  
Duchenne Muscular Dystrophy (DMD) is a progressive, lethal muscle wasting 
disease caused by the absence of dystrophin. DMD is the most common X-linked 
(Xp21.2) recessive disorder and affects 1 in 3,500 boys born. In patients with DMD, 
dystrophin function is completely lost and patients need to use a wheelchair by early 
childhood. Patients with DMD rarely survive into their early 30s and the causes of death 
are frequently respiratory or cardiac failure. Unfortunately there is no cure for DMD.  
Dystrophin is a component of the dystrophin associated protein (DAP) complex, 
linking the cytoskeleton to extracellular matrix components. Dystrophin is one of the 
largest genes in the genome and contains four structural domains including the NH2-
terminal, rod, cysteine-rich, and COOH-terminal domains. The amino (N) terminus binds 
to γ-actin, which anchors dystrophin to cytoskeleton. The central rod domain of 
dystrophin gives flexibility and structural stiffness and the cysteine-rich domain in the 
carboxyl-terminus interacts with the intracellular portion of the β-dystroglycan 
transmembrane protein, anchoring dystrophin to the sarcolemma [Goodwin et al. 2005, 
Heydemann et al. 2007, Celec et al. 2008].  Dystrophin is important for the transmission 
of force from subsarcolemmal actin to the extracellular matrix and protects muscle cells 
from contraction-related muscle damage. Without dystrophin the cell membrane is 
vulnerable to damage and fails to stabilize itself during repeated contractions [Vatta et al. 
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2002] resulting in cell death and leading to necrosis, inflammation and replacement of 
muscle fibers by fat.  
There are three common strategies proposed for treatment of DMD patients: 
pharmacologic agents, gene therapy, and cell therapy [Markert et al. 2009]. 
Pharmacological agents alleviate inflammation and slow progression of the disease, but 
are not enough to cure it because they cannot correct the genetic defect.  In addition, they 
cause side effects from long-term administration similar to corticosteroids [Van Staa et 
al.2000]. Gene therapy for DMD has yielded promising results in animal models, but is 
limited in scope because of the inability to deliver the full-length dystrophin gene due to 
its large size (total size of gene: 2.4mb, mRNA: 14kb, number of exons: 79). To 
circumvent this problem, mini- or micro- dystrophin genes with partial function were 
delivered to muscle in viral vectors. These studies yielded positive results in skeletal 
muscles of animal models for muscular dystrophy [Gregorevic et al. 2004]. However, 
these mini-or micro genes could not alleviate all aspects of cardiac dysfunction [Bostick 
et al. 2008, Townsend et al. 2009]. Another mechanism for gene therapy is to induce 
exon skipping mediated by antisense oligonucleotides to promote read-through of the 
dystrophin gene. By skipping a particular exon at the pre-RNA level functional 
dystrophin can be rescued [Goyenvalle et al. 2010, Cirak et al. 2012]. However the 
oligonucleotides have very low cellular uptake efficiency and personalized oligomers 
based on polymorphism of patients with DMD are needed. For treatment of DMD 
degenerated skeletal and cardiac muscle cells must be replaced to re-gain muscle 
function. Many stem cells can differentiate to cardiomyocytes in vitro, but do not 
maintain cardiac function. However, some stem cells improved cardiac function after 
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transplantation, but rarely differentiate into cardiomyocytes in vivo [Reviewed in 
McNally et al. 2007, Kaspar et al. 2009, Siegel et al. 2012]. 
 
B. Cardiomyopathy in DMD 
Cardiac involvement in DMD is common but occurs at a later age than skeletal 
muscle symptoms [Vatta et al. 2002, Mulder et al. 2009, Farini et al. 2009]. Many studies 
have focused on treatment of skeletal muscle, but increased activity after strengthening 
skeletal muscles provides significant cardiac dysfunction and advanced heart failure 
[Danialou et al. 2001, Goodwin et al. 2005, Townsend et al.2008]. Although there have 
been many studies focused on regenerating or genetically correcting skeletal muscle in 
animal models for DMD, very few studies have been conducted to restore dystrophin in 
the heart and/or replace damaged cardiomyocytes.  
Cardiac involvement in DMD is present in >90% of patients and causes the death 
of 20~40 % of them [Bushby et al. 2003]. Pre-clinical cardiac involvement is observed in 
25% of patients under 6 years old, and clinically apparent cardiomyopathy is diagnosed 
in 59% of them after 10 years of age. Nearly all patients develop cardiomyopathy by 18 
years of age [Nigro et al. 1990]. Specifically, patients with DMD develop dilated 
cardiomyopathy (DCM) characterized by an enlarged left ventricular chamber, thinning 
ventricular wall, and decreased fractional shortening and ejection fraction [Nigro et al. 
1990, Oldfors et al. 1994]. Absence of dystrophin elicits increasing intracellular calcium 
concentration because of the damaged plasma membranes and chronic intracellular 
calcium excess results in the degeneration of cardiomyocytes. The death of 
cardiomyocytes induces an inflammatory response in the dystrophic heart, as 
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macrophages are required to remove dead cells but also lead to fibrosis. Fibrosis is 
formed dominantly in the left ventricular wall, resulting in a loss of flexibility. Stretching 
of the inflexible area from blood filling the chamber induces thinning of the left 
ventricular wall, further decreasing its contractility, and eventually resulting in DCM 
[Kaspar et al. 2009].  Because it is asymptomatic, cardiac involvement is often severely 
advanced when diagnosed, rapidly progressing to heart failure. It is possible to delay the 
progress of cardiac degeneration if cardiac involvement can be regularly monitored from 
the time patients are first diagnosed with DMD. Clinically, it is now possible to improve 
the weakened skeletal muscle and support respiratory function to prolong the life of 
DMD patients [Eagle et al. 2007, Kamogawa et al. 2001]. With the extended lifespan, 
development of cardiomyopathy has become increasingly common in DMD patients, 
underscoring the importance of finding a method to treat cardiomyopathy in these 
patients [Townsend et al. 2009]. It is therefore necessary to develop treatment for both 
skeletal and cardiac muscle in DMD patients.  
 
C.  Animal models for DMD 
Recognizing the need to treat cardiac involvement in DMD, it is essential to 
evaluate DMD animal models to determine whether they develop cardiomyopathy like 
DMD patients. Genetically manipulated mice have been used to study human diseases for 
several reasons: relatively short life cycle, fecundity, similar symptoms to human 
diseases, and effective manipulation of genes. Mdx, mdx/utrn-/- and mdx/MyoD mice 
have been used as murine model to study potential treatments for DMD. Mdx mice have 
a single mutation in the dystrophin gene which is genetically homologous to many DMD 
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patients, but have relatively mild skeletal phenotype and a normal life span, in contrast to 
DMD patients. Mdx mice develop cardiomyopathy with moderate myocardial necrosis 
and fibrosis by 6-8 months of age [Bridges et al. 1986]. Using echocardiography, DCM 
can be detected when mice are approximately 12-months-old, is associated with 
prominent heart pathology, and continues to worsen as mice age [Quinlan et al. 2004]. 
Abnormalities in mdx heart have also been detected by electrocardiography by 21 months 
of age [Bostick et al. 2008]. Although mdx mice develop DCM much later in life than 
patients with DMD they are a valuable model to use for studying therapies for DMD 
cardiac muscle because the mice develop pathology and heart dysfunction similar to 
patients. The mdx/utrn-/- mice lack expression of both dystrophin and utrophin and have 
severe clinical signs of DMD, similar to patients, including severe, progressive skeletal 
muscle pathology, kyphosis, and a severely shortened lifespan. Mdx/utrn-/- mice also 
show cardiac pathologic changes including fibrosis and cardiomyocyte membrane 
damage between 8 and 10 weeks of age [Grady et al. 1997]. However there has been no 
quantitative assessment of these parameters in mdx/utrn-/- mice or a functional study to 
determine whether the mice develop DCM like DMD patients. In Mdx/myoD mice 
cardiomyocyte membranes are extensively damaged and the mice have fibrosis and 
enlarged ventricles at 5 months of age. However functional data including 
echocardiography analysis and quantitation of ventricular dilation have not been reported 
in the mdx/myoD mice [Megeney et al. 1999, Duan 2006].   
There are also other animal models of DMD. The golden retriever muscular 
dystrophy (GRMD) model and the beagle model of canine based x-linked muscular 
dystrophy (CXMD) are the most common canine models of DMD. They have severe 
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clinical symptoms similar to human patients with DMD, and GRMD develop 
cardiomyopathy similar to human DMD patients. However, CXMD have milder cardiac 
involvement than GRMD [Valentine et al. 1989, Yugeta et al. 2006]. Cats that lack 
dystrophin expression develop hypertrophic feline muscular dystrophy (HFMD). 
However these cats do not display muscle fibrosis or severe hypertrophy in diaphragm, in 
contrast to human patients with DMD. In addition it is rare to have severe cardiac failure 
in HFMD cats [Gaschen et al. 1999]. Recently a porcine DMD model has been generated 
by gene targeting with nuclear transfer. These animal have similar skeletal muscle defect 
to human patients with DMD, but development of DCM in this model has not been 
reported [Klymiuk et al. 2011].  
 
D. Stem cell therapies in dystrophin–deficient cardiac muscle of DMD 
Different types of stem cells have been tested for treatment of DMD, including 
embryonic stem cells (ESC) [Crisostomo et al. 2007, Schuldt et al. 2008, Stillwell et al. 
2009, Vertesaljal et al. 2008], induced pluoripotent stem cells (iPS) [Hansson et al. 2009], 
mesoangioblasts [Koh et al. 1995, Minasi et al. 2002, Cossu et al. 2003, Berry et al. 2007, 
Galvez et al. 2008], muscle derived stem cells (MDSCs) [Payne et al. 2005], satellite 
cells and mesenchymal stem cells (MSC) which were derived from bone marrow, 
adipose, and amniotic fluid and membrane [Duan et al. 2006, Gepstein et al. 2006, 
Crisostomo et al. 2007, Laflamme et al. 2007, Schuldt et al. 2008, Vertesaljal et al. 2008, 
Farini et al. 2009, Hansson et al. 2009, Otto et al. 2009]. However, only two of these 
studies have targeted cardiomyopathy in DMD. One of the studies, conducted by T. R. 
Payne and J Huard [Payne et al. 2005], reported restoration of dystrophin expression in 
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mdx/SCID hearts after intracardiac transplantation of MDSCs. However most of the 
dystrophin-positive myocytes expressed a skeletal muscle marker, indicating that the 
donor MDSC differentiate into skeletal muscle cells when transplanted into the heart. 
Most donor-derived myocytes did not form connexin 43 gap junctions, which are 
required for electrical coupling of donor and host cells. Moreover, it is unclear if 
transplanted MDSCs affect the function of dystrophic heart either positively or 
negatively, as heart function was not assessed. In a second study, Koh et al. injected fetal 
cardiomyocytes into the hearts of mdx mice and dystrophic dogs and found 
corresponding dystrophin-expressing cells in the heart and gap junctions between donor 
cell-derived cardiomyocytes and host myocardium. Arrhythmias were not detectable in 
electrocardiography analysis of dogs following cell injection, in agreement with 
histological data demonstrating that the donor cells were integrated into the host tissue 
and express connexin 43 [Koh et al. 1995]. These results are promising, and in agreement 
with engraftment of committed cardiomyocytes to normal heart. However, the use of fetal 
human stem cells is controversial, and they would likely be difficult to obtain for use in 
the clinic. Taken together, stem cells are attractive sources for treatment of DMD 
patients, but have not yet been demonstrated to be feasible for therapeutic use in the 
dystrophic heart of DMD patient.  
 
E. Vessel-associated stem cells: Mesoangioblasts 
Originally mesoangioblasts (or meso-angioblasts) were identified by De Angelis 
et al. [De Angelis et al. 1999] in embryonic dorsal aorta while studying embryological 
origin of skeletal muscle. Later Minasi et al. designated the vessel-related progenitor cells  
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meso-angioblast, as multipotent stem cells, because they  differentiate into most 
mesodermal tissues in vivo and maintain their multipotency in vitro and in vivo [Minasi 
et al., 2002]. Mesoangioblasts have been isolated from embryonic dorsal aorta [Minasi et 
al. 2002, Galvez et al. 2008], postnatal aorta [Berry et al. 2007], heart [Galvez et al. 
2008], skeletal muscles [Sampaolesi et al. 2006, Morosetti et al. 2007]. Cardiac 
mesoangioblasts isolated from atria and ventricles have been transplanted to infarcted 
heart, increasing ventricular wall thickness and fractional shortening without ventricular 
chamber diameter. Injected cardiac mesoangioblasts also differentiated into 
cardiomyocytes and expressed sarcomeric myosin [Galvez et al. 2008].  These data 
demonstrated that cardiac muscle-derived mesoangioblasts regenerate cardiac muscle.  
We have isolated multipotent mesoangioblasts (ADM) from aorta of wild-type 
newborn mice.  These cells have a different cell surface marker profile than the 
mesoangioblasts isolated from skeletal or cardiac muscle muscles, or bone marrow, or 
embryonic dorsal aorta, but are most similar to those isolated from embryonic dorsal 
aorta, [Lei et al. 2011]. Our group has reported that ADM differentiate into smooth 
muscle cells, skeletal myotubes, oligodendrocyte precursors, and pre-adipocytes [Berry et 
al. 2007, Lei et al. 2011]. In addition, transplantation of ADM into the gastrocnemius 
resulted in engraftment into skeletal muscle, restoration of dystrophin expression and a 
decrease in the number of damaged muscle fibers in mdx/utrn-/- mice [Berry et al. 2007]. 
This study suggested that ADM might be an excellent source for stem cell therapeutic 
purpose to treat DMD with damaged skeletal muscles. These results prompted us to 
perform this study to determine if ADM might improve damaged cardiac condition in 
DMD as well.   
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F. ADM as treatment of cardiomyopathy in murine models for DMD  
The goal of this study was to examine the capacity of ADM to serve as a 
therapeutic approach in the heart of murine models for DMD to determine whether they 
had similar benefit in dystrophic heart as in the dystrophic skeletal muscles. Therefore I 
hypothesized that ADM will ameliorate DCM in murine model of DMD.  
For addressing this goal I established three aims. 1) To determine whether the 
cardiomyopathy in the mdx/utrn-/- murine model for DMD is similar to DMD patients. 
This aim focused on characterizing the heart function and pathology in mdx/utrn-/- mice 
to determine whether it was similar to DMD patients, and whether mdx/utrn-/- mice are a 
feasible disease animal model to use in pre-clinical studies for therapy for 
cardiomyopathy in DMD. 2) To determine whether ADM differentiate into 
cardiomyocytes. This aim focused on inducing differentiation of ADM into 
cardiomyocytes in vitro and determining cell fate in vivo following transplantation into 
the dystrophic heart. 3) To determine whether ADM transplantation improved cardiac 
function and pathology in mdx and mdx/utrn-/- mice.  This aim used echocardiography 
and histology to study whether ADM transplantation had a positive effect on dystrophic 
hearts. 
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1Chapter II 
Cardiac dysfunction and pathology in the dystrophin and utrophin-deficient 
mouse during development of dilated cardiomyopathy 
 
A. Introduction 
Cardiac involvement in Duchenne muscular dystrophy (DMD) is present in nearly 
all patients by adulthood [Nigro et al. 1990, Bushby et al. 2005, Wagner et al. 2007] and 
causes the death in approximately 20% of them [Bushby et al 2003, Baxter 2006, 
Spurney 2011]. Specifically, patients with DMD develop dilated cardiomyopathy 
characterized by an enlarged left ventricular chamber, thinning ventricular wall, and 
decreased fractional shortening and ejection fractions [Nigro et al. 1990]. Cardiac 
involvement in DMD has increased as a result of recent improvements in ambulation and 
respiratory support in patients [Kamogawa et al. 2001, Wagner et al. 2007, Kaspar et al. 
2009, Spurney 2011]. These advances have made it possible to prolong the life of DMD 
patients [Eagle et al. 2002, Eagle et al. 2007]. However, with the extended lifespan, 
development of cardiomyopathy is increasingly common in the later stage of the disease.  
There is evidence that ACE inhibitors, steroids, and beta blockers can delay 
decreases in heart function and development of ventricular dilation, and prolong the life 
of DMD patients [Bridges 1986, Simonds et al. 1998, Quinian et al. 2004, Duboc et al. 
                                                      
 1 This chapter appeared in its entirety in Neuromuscular Disorders journal and is referred 
 to later in this dissertation. This article is reprinted with the permission of the publisher 
 and is available from http://www.elsevier.com or http://dx.doi.org and using 
 DOI:10.1016/j.nmd.2011.07.003 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2005, Duboc et al. 2007, Townsend et al. 2009, Spurney 2011]. However, there is still no 
cure for cardiomyopathy in these patients [Townsend et al. 2009]. It is therefore valuable 
to have dystrophin-deficient animals with cardiac pathology and dysfunction similar to 
DMD patients on which to test experimental therapies. Genetically manipulated mice 
have been used to study human diseases and are good model organisms for several 
reasons: a relatively short life cycle, fecundity, similar symptoms to human diseases, and 
effective manipulation of genes. 
There are three strains of dystrophin-deficient mice: the mdx, mdx/utrn−/− 
dystrophin/utrophin-deficient, and mdx/myoD−/− mice. Mdx mice have a single mutation 
in the dystrophin gene identical to many DMD patients, but have relatively mild skeletal 
muscle pathology that is not progressive, as well as a normal life span, in contrast to 
patients. However, similar to DMD patients, mdx mice develop moderate myocardial 
necrosis and fibrosis, detectable by 6–8 months of age [Bridges 1986], and prominent 
heart pathology appears when mice are approximately 12 months old and continues to 
worsen as mice age [Quinian et al. 2003], resulting in development of dilated 
cardiomyopathy at 12–21 months of age [Quinian et al. 2004, Bostick et al. 2008]. 
Because the mice develop cardiomyopathy, similar to patients, mdx is a valuable model 
to use for studying therapies for DMD cardiac muscle. Unfortunately, using mdx mice to 
mimic dilated cardiomyopathy in DMD is time-consuming and expensive because of the 
length of time necessary for development of pathology and ventricular dilation. Similarly, 
mdx/myoD mice also develop extensive damage to cardiomyocyte membranes, fibrosis, 
and enlarged ventricles at 5 months of age, although functional data by echocardiography 
and quantitation of ventricular dilation have not yet been performed [Duan 2006, 
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Megeney et al. 1999]. An animal that develops cardiomyopathy similar to DMD patients 
in a shorter time course would be cost-effective and would also facilitate the pace of the 
research. Mdx/utrn−/− dystrophin/utrophin-deficient mice lack expression of both 
dystrophin and utrophin, and have severe and progressive skeletal muscle pathology, 
spinal curvature, limited mobility, and a severely shortened lifespan, similar to patients 
[Grady et al. 1997]. Mdx/utrn−/− dystrophin/utrophin-deficient mice have also been 
reported to develop cardiac pathology including cardiomyocyte membrane damage and 
necrosis, between 8 and 10 weeks of age [Grady et al. 1997]. However there has not been 
a quantitative assessment of these parameters in mdx/utrn−/− dystrophin/utrophin-
deficient mice, and no functional analysis has been reported to determine whether the 
mice develop dilated cardiomyopathy similar to DMD patients. 
In this study I characterized the cardiomyopathy and its development in 
mdx/utrn−/− dystrophin/utrophin-deficient mice, including functional and histological 
changes as the mice age. Using echocardiography and analysis of post-mortem tissue, I 
demonstrated the evolution of cardiomyopathy in mdx/utrn−/− dystrophin/utrophin-
deficient mice, and determined that it is functionally and histologically similar to patients 
with DMD. In addition, because dilated cardiomyopathy occurs within weeks, at an 
earlier age than mdx or mdx/myoD mice, the mdx/utrn−/− dystrophin/utrophin-deficient 
mice are an alternative, cost-effective model for testing potential therapeutic approaches 
for DMD-associated cardiac muscle disease. 
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B.  Materials and Methods 
B-1. Mice 
All animal use was approved by the University of Illinois Institutional Animal 
Care and Use Committee. Mdx/utrn−/− dystrophin/utrophin-deficient mice were generated 
by mating mdx/utrn+/− male and female mice [Grady et al. 1997], and the progeny were 
genotyped as previously described [Burkin et al. 2001, Grange et al. 2002]. Age-matched 
wild-type controls were used for comparison in all experiments. Echocardiography was 
performed and mice were subsequently weighed and euthanized. 
 
B-2. Echocardiography 
Mdx/utrn−/− dystrophin/utrophin-deficient and wild-type hearts were examined by 
echocardiography at 5, 10, and 15 weeks of age. GE/Vingmed ultrasound Vivid7 was 
used for performing echocardiographs. Mice were anesthetized by halothane mixed in 
mineral oil. Before echocardiography the hair was clipped around the chest. Ultrasound 
gel was placed on the transducer (10S) and scanning was performed for approximately 
10 min. Mdx/utrn−/− dystrophin/utrophin-deficient and wild-type mice were presented 
randomly to the echocardiographer (R.O.), who was unaware of the genotype. 
Two-dimensional M-mode echocardiography was used to measure internal 
ventricular septum thickness, left ventricular internal dimension, and left ventricular 
posterior wall thickness, and these values were used to calculate left ventricular fractional 
shortening, end-diastolic volume, end-systolic volume, stroke volume, and ejection 
fraction. Left ventricular fractional shortening (FS) was calculated by the change between 
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filling (diastole; LVd) and emptying (systole; LVs) of the ventricle {(LVd–
LVs)/LVD × 100}. End-diastolic volume (EDV) was calculated by 
{7×(LVd)3}/(2.4 + LVd). End-systolic volume (ESV) was calculated as EDV−stroke 
volume (SV). Stroke volume (SV) was calculated as EDV−ESV. Ejection fraction (EF) is 
equal to {(LVEDV−LVESV)/LVEDV × 100}. The equations for EF and EDV were used 
according to the Teicholz method. 
 
B-3. Statistics 
Echocardiography data were analyzed using the Proc Mixed procedure of SAS 
(SAS Inst. Inc., Cary, NC). The statistical model included effects of genotype, age, and 
their interaction, as fixed effects. There were six blocks, representing two genotypes by 
three time points. Block was a random effect. Differences between wild-type mice and 
mdx/utrn−/− dystrophin/utrophin-deficient type mice within each time point and among 
time points within each type of mice were tested by pair-wise comparisons when the 
main effects were significant. 
 
B-4. Tissue collection 
Hearts were dissected, weighed, and frozen in liquid nitrogen-cooled 2-
methylbutane. Frozen hearts were sectioned to 10 µm thickness using a Thermo Fisher 
Scientific Shandon Cryotome FSE Cryostat (Pittsburgh, PA), at −17 °C. 
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B-5. Masson’s trichrome staining 
Fibrosis was examined by analyzing collagen content in the heart tissue, 
visualized by Masson’s Trichrome stain. Briefly, frozen heart sections were warmed up 
to room temperature, and incubated in Bouin’s solution at 60°C for 1 h. After washing, 
the sections were stained with Weigert’s iron Hematoxylin, and then Biebrich scarlet-acid 
fuchsin solution followed by phosphomolybdic/phosphotungstic acid staining. After a 
quick water rinse, slides were placed in aniline blue solution, and were then placed into 
1% acetic water solution followed by 95% and absolute alcohols and into xylene. Three 
slides per heart were used for quantitation of fibrosis. Images were captured with a Leica 
DFC320 Digital Camera (W. Nuhsbaum, Inc., McHenry, IL), mounted on a Leica 
Inverted DMI 4000B microscope (Nuhsbaum, McHenry, IL). Regions of 
fibrosis/Trichrome staining were quantitated using Image Pro Plus software 
(MediaCybernetics, Bethesda, MD). 
 
B-6. Immunofluorescent detection of collagen I 
Frozen heart sections were fixed with 3.7% formaldehyde for 10 min, and blocked 
with PBS containing 1% BSA and 5% horse serum for 1 h. The sections were incubated 
with anti-collagen type I rabbit polyclonal antibody (Abcam, Cambridge, MA) for 1 h. 
Sections were then washed and incubated with donkey anti-rabbit TRITC antibody 
(Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) for 1 h. Slides were 
washed 3 times with 1xPBS, and mounted onto slides (Fisher Scientific, Pittsburgh, PA) 
using Vectashield mounting medium containing DAPI (Burlingame, CA). Images were 
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acquired with a Retiga 2000R digital camera (Q-imaging, Surrey, BC) mounted on a 
Leica Inverted DMI 4000B microscope (Nuhsbaum, McHenry, IL), and colors were 
assigned and images merged using Image Pro Plus software (MediaCybernetics 
Bethesda, MD). 
 
B-7. Evan’s Blue Dye 
One percent Evan’s Blue Dye was prepared in phosphate-buffered saline (PBS, 
pH 7.5), passed through a 0.22 µm filter (Millpore, USA). Mice were injected 
intraperitoneally with 1% volume of EBD relative to body weight. After injection mice 
were housed in normal animal care conditions, and euthanized by CO2 gas after 24 h. 
Hearts were dissected, and frozen by 2-methylbutane cooled by liquid nitrogen. Frozen 
sections were fixed with 3.7% formaldehyde for 10 min, and immunostained with FITC-
conjugated wheat germ agglutinin for 5 min. After washing with PBS the sections were 
mounted using Vectashield mounting medium containing DAPI (Vector Laboratories, 
Burlingame, CA). Images of Evans Blue Dye stain, FITC-conjugated wheat germ 
agglutinin, and DAPI were acquired with a Retiga 2000R digital camera (Q-imaging, 
Surrey, BC), mounted on a Leica Inverted DMI 4000B DMIL microscope (Nuhsbaum, 
McHenry, IL) and colors were assigned and images merged using Image Pro Plus 
software (MediaCybernetics, Bethesda, MD). 
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B-8. Hematoxylin and Eosin staining 
Frozen sections were fixed in 95% ethanol, and then placed in 70% ethanol for 
2 min. Sections were stained with Gills Hematoxylin (Fisher Scientific, Pittsburgh, PA) 
for 5 min, followed by a 2 min rinse in running H2O, and then placed in Scott’s solution. 
Sections were immersed in eosin for 5 min, gradually dehydrated in ethanol, and cleared 
in xylene. Images for Trichrome staining of collagen or H&E were acquired using a 
Leica DMIL microscope, Leica Applications Suite Imaging Software (version 2.8.1), and 
a Leica DFC320 Digital Camera (W. Nuhsbaum, Inc., McHenry, IL). 
 
B-9. Transmission electron microscopy 
Heart tissues from mdx/utrn−/− and C57Bl6 mice at 15 weeks of age were frozen 
in liquid nitrogen-cooled 2-methybutane. Samples were prepared and embedded for 
transmission electron microscopy (TEM) as described in Miller [Miller et al. 2001]. For 
TEM, 60–100 nm ultrathin sections were cut from embedded heart tissue samples with a 
Diatome Ultra 45° knife (DiATONE USA, PA). Sections were floated off onto water and 
picked up with 200 and 300 mesh copper grids and stained with uranyl acetate and lead 
citrate. Prepared samples were observed on an H600 Hitachi Electron Microscope 
(Hitachi High-Technologies Europe GmbH, Germany) at 75 kV. Images were taken onto 
Kodak Electron Microscopy Film 4489, developed and scanned in on a Microtek 
ScanMaker 9800XL with TMA (Microteck International, Inc., Taiwan) at 3200 dpi 
original scan. 
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C. Results 
C-1. Mdx/utrn−/− dystrophin/utrophin-deficient mice develop dilated 
cardiomyopathy, detected by echocardiography 
Echocardiography of wild-type and mdx/utrn−/− dystrophin/utrophin-deficient 
mice was performed at 5, 10, and 15 weeks of age, using motion (M)-mode scans to 
detect anatomical and functional parameters of the heart (Table 1-A and Fig. 1). At age 
5 weeks salient differences were not detected between mdx/utrn−/− dystrophin/utrophin-
deficient and wild-type control mice with the exception of an accelerated heart rate. 
However, at 10 weeks of age there were multiple parameters that were significantly 
different. A decrease in the thickness of the left ventricular posterior wall in mdx/utrn−/− 
dystrophin/utrophin-deficient mice at both diastole and systole was observed (Table 1-A). 
The interventricular septum was also significantly thinner in mdx/utrn−/− 
dystrophin/utrophin-deficient mice than age-matched wild-type mice at diastole. 
Mdx/utrn−/− dystrophin/utrophin-deficient hearts continued to deteriorate between 10 and 
15 weeks, and a greater number of significant differences were prominent at 15 weeks of 
age. The left ventricular posterior wall was significantly thinner in a time-dependent 
manner in comparison to age-matched wild-type mice through 15 weeks of age (Table 1-
A). In addition, the left ventricular internal dimension during diastolic phase gradually 
enlarged, reaching a statistically significant difference in size compared to wild-type 
heart (Table 1-A). An increase in left ventricular internal dimension at systole (Table 1-
A) was also observed although not statistically significant. 
There were also significant changes in systolic and diastolic function in 
mdx/utrn−/− dystrophin/utrophin-deficient heart at 15 weeks. Fractional shortening, which 
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represents systolic function, was lower in mdx/utrn−/− dystrophin/utrophin-deficient 
hearts compared to age-matched wild-type mice hearts (Table 1-A and Fig. 1A). Ejection 
fraction also significantly decreased in mdx/utrn−/− dystrophin/utrophin-deficient versus 
wild-type mice (Table 1-A and Fig. 1B), and end-diastolic volume and end-systolic 
volume were significantly increased (Table 1-A and Fig. 1C). Differences in the overall 
heart and body weight ratio of the mdx/utrn−/− dystrophin/utrophin-deficient and wild-
type mice could account for the observed differences in the echocardiograph parameters. 
As a result, the heart and body weight were recorded for each mouse following 
echocardiography, as well as their ratio, and were compared between genotypes (Table 1-
B). Mdx/utrn−/− dystrophin/utrophin-deficient mice are significantly smaller than wild-
type mice; however, there was not a significant difference in heart and body weight ratio 
between mdx/utrn−/− dystrophin/utrophin-deficient and wild-type mice (Table 1-B). 
 
C-2. Cardiac fibrosis is present and increases over time in dystrophin/utrophin-
deficient cardiac muscle 
Fibrosis at the short axis of mdx/utrn−/− dystrophin/utrophin-deficient hearts was 
detected by Masson’s Trichrome staining for collagen, [ Payne et al. 2005, Duan 2006, 
Bostick et al. 2008, Spurney et al. 2008, Au et al. 2011], as well as with an antibody to 
collagen I. Trichrome staining was used to compare collagen-rich regions in mdx/utrn−/− 
dystrophin/utrophin-deficient hearts with age- matched wild-type mice. There were small 
patches of collagen in both the left and right ventricles of mdx/utrn−/− 
dystrophin/utrophin-deficient, but not wild-type, mice at 5 weeks of age (Figs. 2B and 3). 
Fibrosis was detected at 10 weeks of age in similar regions (Figs. 2D and 3), and by the 
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age of 15 weeks, larger regions of fibrosis were visualized in both right and left 
ventricles, and septum (Figs. 2F and 3). Fibrosis was detected throughout the heart at all 
ages, with increasing size of lesions at late stages of disease, approaching the maximum 
lifespan of the mdx/utrn−/− dystrophin/utrophin-deficient mice (Fig. 3). Overall, 
mdx/utrn−/− dystrophin/utrophin-deficient mice at age of 15 weeks had approximately 17 
times more cardiac fibrosis than those at age of 5 weeks, and 10 times more than those at 
age of 10 weeks. 
 
C-3. Membrane damage in cardiomyocytes and cellular necrosis are present in 
ventricles of mdx/utrn−/− dystrophin/utrophin-deficient mice 
To examine other pathological features of mdx/utrn−/− dystrophin/utrophin-
deficient mice Evan’s Blue Dye and hematoxylin and eosin staining were performed. 
Evans Blue Dye binds the serum protein albumin, and therefore accumulates in muscle 
cells or fibers that have sustained membrane damage, allowing serum proteins to leak 
inside the cell [Hamer et al. 2002, Miller 2007]. Similar with fibrosis formation, 
cardiomyocytes with Evan’s Blue Dye infiltration were present in both the right and left 
ventricles (Fig. 4A and B, arrowheads, C and D, arrows), as well as the interventricular 
septum of mdx/utrn−/− dystrophin/utrophin-deficient mice at 15 weeks of age (Fig. 4A 
and B, arrows). Evan’s Blue Dye infiltration was also detected in the heart of mdx mice 
at 15 weeks of age (Fig. 4E and F), but in contrast to the in mdx/utrn−/− 
dystrophin/utrophin-deficient mice, was only detected in the septum of the mdx mice 
(Fig. 4, white arrows) and not in the right or left ventricles. Preliminary results indicate 
that there are higher numbers of Evan’s Blue Dye-positive cells in mdx/utrn−/− 
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dystrophin/utrophin-deficient heart than in the mdx heart (0.51% in mdx/utrn−/− heart 
compared to .02% of total area in the mdx heart). Necrosis was also detected in both 
ventricles of the mdx/utrn−/− dystrophin/utrophin-deficient heart at 15 weeks of age (Fig. 
4G, arrow), but not in mdx heart at this age (Fig. 4H). 
 
C-4. Ultrastructural changes in mdx/utrn−/− dystrophin/utrophin-deficient 
cardiomyocytes 
Transmission electron microscopy was performed on tissue from the ventricles of 
15 week old wt and mdx/utrn−/− dystrophin/utrophin-deficient cardiac muscle (Fig. 5). In 
wt cardiomyocytes, mitochondria were regularly arranged between myofibrils, and were 
homogenous in size (Fig. 5A and B). In contrast, mitochondria in mdx/utrn−/− 
dystrophin/utrophin-deficient cardiomyocytes were disorganized, frequently disrupting 
myofibrils (Fig. 5C and D). Mitochondria were also irregularly shaped and the 
organization of cristae was altered (Fig. 5D). In addition, very few T-tubules were visible 
in mdx/utrn−/− dystrophin/utrophin-deficient cardiomyocytes in comparison to wt cells 
(Fig. 5B and D). 
 
D.   Discussion 
Cardiac involvement in DMD patients has not been studied as extensively as 
skeletal muscle pathology and disease progression, in part because damaged skeletal 
muscle limits the movement of patients, and prevents overt symptoms of cardiac 
involvement. As a result, most of the studies in the last decade have focused on 
improving damaged skeletal muscles or supporting the respiratory system in Duchenne 
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patients. These studies have yielded promising results for management of these 
symptoms in DMD patients, prolonging life by several years, but resulting in significant 
clinical cardiac involvement in older patients with DMD [Eagle et al. 2002, Eagle et al. 
2007, Kohler et al. 2009]. In contrast to the large number of studies focused on repairing 
or improving skeletal muscle, few studies have focused on treatment of cardiac muscle in 
DMD patients. However, recognizing the prevalence of cardiac involvement in this 
disease, the need to understand cardiomyopathy in DMD patients has resulted in an 
increase in the number of studies on this topic. It is therefore important to identify 
animals that develop cardiomyopathy similar to that of Duchenne patients, for use in 
preclinical studies to alleviate cardiac dysfunction resulting from dystrophin-deficiency. 
Using echocardiography to monitor heart function and other parameters, we now 
report the development of progressive, dilated cardiomyopathy in the mdx/utrn−/− 
dystrophin/utrophin-deficient mouse, similar to patients. At 5 weeks of age, the only 
significant difference between the wild-type and mdx/utrn−/− dystrophin/utrophin-
deficient heart is an elevated heart rate in the dystrophic mice. An elevated heart rate, or 
tachycardia, has been documented in patients with DMD [ Heymsfield et al. 1978, 
Yotsukura et al. 1995, Bhattacharyya et al. 1997, Gulati et al. 2005, Kirchmann et al. 
2005], at ages as young as 4 years [Heymsfield et al. 1978] and in patients as old as 
24 years [Yotsukura et al. 1995]. Similarly, the difference in heart rate between the 
mdx/utrn−/− dystrophin/utrophin-deficient and wild-type mice is present at the earliest 
time point and persists until 15 weeks of age, with increasing statistical significance over 
time (Table 1). The presence of chronic tachycardia in DMD patients and mdx/utrn−/− 
dystrophin/utrophin-deficient mice may exacerbate cardiomyopathy, as chronic 
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tachycardia can result in left ventricular dysfunction and dilation [Umana et al. 
2003, Mohamed et al. 2007], including thinning of both the left and right ventricular 
walls. 
At 10 and 15 weeks of age, changes indicative of dilated cardiomyopathy were 
apparent in the mdx/utrn−/− dystrophin/utrophin-deficient mice. These changes were 
consistent with the clinical criteria for diagnosis of dilated cardiomyopathy, which 
include reduced left ventricular function assessed by a decrease in fractional shortening 
and ejection fraction, and an increase in end-diastolic volume [Mestroni et al. 1999, 
Taylor et al. 2006]. Left ventricular fractional shortening is a common measurement of 
left ventricular function representing the ventricular size change between filling (diastole) 
and emptying (systole) of the ventricle. There is a significant decrease in fractional 
shortening in 15 week old mdx/utrn−/− dystrophin/utrophin-deficient mice (29.64%) in 
comparison to age-matched wild-type mice (38.62%). In fact, fractional shortening 
increases with age in wild-type mice, rather than decreasing, as in the mdx/utrn−/− 
dystrophin/utrophin-deficient mice. Ejection fraction, or the blood volume leaving the left 
ventricle with each contraction, is also significantly decreased in 15 week old mdx/utrn−/− 
dystrophin/utrophin-deficient mice (62.29%), in contrast to age-matched wild-type mice, 
which have an increase in ejection fraction as they mature (77.49%). In addition, there is 
also a difference in end-diastolic volume, which is the blood volume of the distended left 
ventricle at the end stage of diastole, often represented as the preload or force stretching 
the myocardium, between mdx/utrn−/− dystrophin/utrophin-deficient mice and wild-type 
mice. Mdx/utrn−/− dystrophin/utrophin-deficient mice have significantly increased end-
diastolic volume (0.0841 ml) compared to age-matched wild-type (0.0533 ml), indicating 
  24 
that more blood remains in the left ventricle following each contraction and therefore less 
blood is pumping out to the body. Together, the changes in these parameters support a 
gradual decrease in left ventricular function in the mdx/utrn−/− dystrophin/utrophin-
deficient mouse heart. This also correlates with a gradual thinning of the left ventricular 
wall, and an increased overall diameter of the left ventricle, with a significantly larger 
chamber than that of wild-type mice by 15 weeks of age. In summary, the 
echocardiograph data indicate that mdx/utrn−/− dystrophin/utrophin-deficient mice 
develop dilated cardiomyopathy that is similar to Duchenne patients, with a sequence of 
events also similar to the human disease. 
Mdx mice also exhibit dilated cardiomyopathy similar to DMD patients, but 
develop the condition more slowly than do the mdx/utrn−/− dystrophin/utrophin-deficient 
mice. Mdx mice develop a decrease in fractional shortening by 40–43 weeks of age 
[Quinlan et al. 2004, Spurney et al. 2008, Au et al. 2010], but do not exhibit differences 
in this parameter at earlier time points examined, including 8 and 29 weeks of age 
[Quinlan et al. 2004]. Ejection fraction is also decreased in mdx mice by 40 weeks of age 
[ Spurney et al. 2008] and ventricular dilation is observed by 36–42 weeks of age [ 
Quinlan et al. 2004, Spurney et al. 2008] but not at 8 or 29 weeks of age [ Quinlan et al. 
2004]. Mdx and mdx/utrn−/− dystrophin/utrophin-deficient mice therefore both develop 
symptoms indicating dilated cardiomyopathy but the mdx/utrn−/− dystrophin/utrophin-
deficient mice exhibit changes much more rapidly than the mdx mice. Histopathology 
corresponding to the decline in heart function was detected in mdx/utrn−/− 
dystrophin/utrophin-deficient cardiac muscle. Regions of fibrosis were detected in right 
and left ventricles, as well as the interventricular septum, of mdx/utrn−/− 
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dystrophin/utrophin-deficient mice, with the most prominent involvement at the lateral 
left ventricular wall, where all mice examined had fibrosis at 5, 10, and 15 weeks of age. 
As the mice advanced in age, fibrosis was detected more frequently in the interventricular 
septum and later in the right ventricular wall. The size of the fibrotic areas directly 
correlated with increasing age, and was larger at the latest stage of the disease when 
ventricular dysfunction was also greatest. In addition, the large areas of fibrosis in 
15 week old mice were in the outer half of the ventricular wall (Fig. 2F), which is 
consistent with, and distinctive for, Duchenne muscular dystrophy [reviewed in Kaspar 
and Allen 2009]. Damage to myocardial cell membranes was also detected in the 
mdx/utrn−/− dystrophin/utrophin-deficient mice, as previously reported by Grady et al. 
[Grady et al. 1997], by examining the presence of serum proteins within cardiomyocytes 
using Evan’s Blue Dye to bind albumin. The localization of damaged cells was not 
previously reported. In our study, Evan’s Blue Dye-positive cells were detected within 
the left and right ventricles as well as the interventricular septum (Fig. 4), correlating 
with regions of fibrosis. This differs from the mdx mice in our study, which had Evan’s 
Blue Dye-positive cardiomyocytes at 15 weeks of age, but only in the septum. This is in 
agreement with another study in which Evan’s Blue Dye-positive cells were reported in 
3 month old mice [Erp et al. 2010]. A second study reported the absence of Evan’s Blue 
Dye-positive cells in the mdx heart at 10 weeks of age [Grady et al. 1997]. Collectively, 
these data suggest that membrane damage to cardiomyocytes occurs between 10 and 
15 weeks of age in mdx mice as well as in the mdx/utrn−/− dystrophin/utrophin-deficient 
mice. Cellular necrosis had previously been detected in cardiac muscle of the mdx/utrn−/− 
dystrophin/utrophin-deficient mice [ Grady et al. 1997] but the localization not reported. 
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We also detected necrosis, in both the left and right ventricles. The cell membrane 
damage and necrosis in the mdx/utrn−/− dystrophin/utrophin-deficient mice are consistent 
with reports of myocardial damage in Duchenne patients [Ramaciotti and Iannaccone 
2003, Kirchmann et al. 2005]. 
Ultrastructure analysis of cardiomyocytes from 15 week old mdx/utrn−/− 
dystrophin/utrophin-deficient mice revealed disruptions in myofibrils in the 
cardiomyocytes, which would likely negatively impact cell contraction and heart 
function. Myofibril disruptions were frequently due to mislocalized, disorganized 
mitochondria. We also observed abnormalities in mitochondria size and shape within the 
cell as well as cristae organization within the mitochondria (Fig. 5). A previous report of 
the ultrastructure of cardiomyocytes in 10 week old mdx/utrn−/− dystrophin/utrophin-
deficient mice did not indicate that abnormalities in mitochondria were present [Sanford 
et al. 2005]. However, similar results have been reported in cardiomyocytes of δ-
sarcoglycan (δ-SG)-deficient hamsters that also develop dilated cardiomyopathy and do 
not express dystrophin in the heart [Kawada et al. 2003]. In that study, irregularly shaped 
mitochondria that varied in size and had loosely arranged cristae were detected at 
25 weeks of age, although the overall organization of mitochondria was not reported to 
be abnormal. An increase in the numbers of mitochondria present in cardiomyocytes was 
also reported in 1–6 year old dogs with canine X-linked muscular dystrophy, although 
there was no evidence of abnormal organization of mitochondria within the cells, changes 
in shape of the mitochondria, or organization of cristae within the mitochondria 
[Valentine et al. 1989]. Although not specifically linked to alterations in members of the 
dystrophin–glycoprotein complex, mitochondrial abnormalities have also been reported 
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in patients with dilated cardiomyopathy in the clinic. Mitochondrial degeneration has 
been reported in children [NSimonds et al. 1999] and adults [Sekiguchi et al. 1978] 
reviewed in [NSimonds et al. 1999] with dilated cardiomyopathy, and mitochondriosis, or 
increased numbers of mitochondria, is present in cardiomyocytes of children with dilated 
cardiomyopathy [Schmaltz et al. 1990]. Oversized mitochondria and abnormalities in 
cristae were also observed in patients with dilated cardiomyopathy [Arbustini et al. 
1998]. In addition, patients with mutations in mitochondrial DNA develop dilated 
cardiomyopathy [Arbustini et al. 1998], suggesting that mitochondrial defects and 
dysfunction may contribute to development of dilated cardiomyopathy. Accumulation of 
abnormal mitochondria in mdx/utrn−/− cardiac muscle may affect the metabolic rate in the 
heart and thereby exacerbate the heart dysfunction resulting from loss of cardiomyocytes. 
The earlier onset of fibrosis and cardiac dysfunction in mdx/utrn−/− mice, in 
comparison to mdx mice, suggests that utrophin may functionally compensate for 
dystrophin. Utrophin-deficient mice do not exhibit a detectable cardiac phenotype 
[Deconinck et al. 1997], and Grady et al. reported that there was no detectable 
histological change in utrophin-deficient cardiac muscle [Grady et al. 1997]. However, 
Janssen et al. [Janssen et al. 2005] reported that mdx/utrn−/− dystrophin/utrophin-deficient 
mice exhibit contractile dysfunction to a greater degree than mdx mice, indicating that 
utrophin may be able to functionally compensate for dystrophin to some extent. This 
correlated with the up regulation and re-localization of utrophin in mdx hearts [Pons et al. 
1994]. In mdx heart, utrophin localization is disrupted and the protein is expressed in 
regions of cardiomyocytes normally occupied by dystrophin, but not utrophin [ Pons et 
al. 1994]. 
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Based on the echocardiograph data and histological assays, mdx/utrn−/− 
dystrophin/utrophin-deficient mice develop dilated cardiomyopathy similar to DMD 
patients, within 15 weeks (Fig. 6). The use of the mdx/utrn−/− dystrophin/utrophin-
deficient mice for preclinical studies to treat the cardiomyopathy therefore may be 
advantageous over other mouse models for DMD, including the mdx and the mdx/myoD 
mouse. The latter two mouse models for DMD develop cardiomyopathic changes similar 
to patients as well, but in longer periods of time, 6–21 months [Bridges 1986, Quinlan et 
al. 2004, Bostick et al. 2008], and 5 months [Megeney et al. 1999, Duan 2006] 
respectively. Studies could be conducted at an accelerated pace in the mdx/utrn−/− 
dystrophin/utrophin-deficient mice, and would cost considerably less. However, 
mdx/utrn−/− dystrophin/utrophin-deficient mice have severe and progressive skeletal 
muscle disease as well as cardiomopathy, and as a result are fragile and may not survive 
15 weeks, limiting their use for long-term studies. As a result, a combination of the three 
mouse models would allow both short- and long-term preclinical studies for potential 
therapies (Fig. 6). 
 In conclusion, the mdx/utrn−/− dystrophin/utrophin-deficient mice have previously 
been established as an excellent phenotypic model for Duchenne muscular dystrophy 
because of the many similarities to patients in the development of skeletal muscle 
pathology [Grady et al. 1997]. Our study demonstrates that the mdx/utrn−/− 
dystrophin/utrophin-deficient mouse may also serve as a tool for simulating cardiac 
muscle dysfunction and pathology in Duchenne patients, developing dilated 
cardiomyopathy similar to patients with DMD in both functional and histological aspects 
(Fig. 6; [ Frankel and Rosser 1976, Miyoshi 1991, Moriuchi et al. 1993, Sasaki et al. 
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1998, Nishimura et al. 2001, Connuck et al. 2008]). Additionally, the progression and 
time frame of cardiomyoapthy in the mdx/utrn−/− dystrophin/utrophin-deficient mice is 
similar to that of Duchenne muscular dystrophy patients (Fig. 6). As a result, mdx/utrn−/− 
dystrophin/utrophin-deficient mice may be useful for advancing understanding of 
cardiomyopathy in Duchenne muscular dystrophy, as well as for testing potential 
experimental therapeutic approaches for cardiomyopathy in Duchenne patients. 
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Figure 1. Mdx/utrn-/- left ventricular function at 15 weeks of age, in comparison to age-matched 
wild-type mice 
 
 
There is a significant decrease in Mdx/utrn-/- left ventricular function at 15 weeks 
of age, in comparison to age-matched wild-type mice.   Fractional shortening (A), 
ejection fraction (B), and end diastolic volume (C), of mdx/utrn-/- and wild-type mice at 
ages of 5, 10, and 15 weeks.   *: p<0.05. 
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Figure 2. Fibrosis in mdx/utrn-/- cardiac muscle 
 
 
 
 
 
 
 
 
 
 
 
Fibrosis in mdx/utrn-/- cardiac muscle.  Trichrome staining of the left ventricle of 
mdx/utrn-/- (B, D, F) and age-matched wild-type (A, C, E) mice indicates that fibrosis is 
present in the mdx/utrn-/- heart as early as 5 weeks (B, arrow), and increases at 10 and 15 
weeks of age (D, F, arrows). 4x
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Figure 3. Increased fibrosis in the ventricles of mdx/utrn-/- mice over time 
There is a significant increase in 
fibrosis in the ventricles of mdx/utrn-/- 
mice over time.  A, short-axis view of 
the heart, with numbers designating 
specific regions where fibrosis was 
detected.  RV, right ventricle; LV, left 
ventricle.  B, localization of fibrosis in 
the mdx/utrn-/- cardiac muscle over 
time, including the number of mice 
with fibrosis in the regions indicated in 
‘A’.  C, Quantitation of fibrosis in 
mdx/utrn-/- or wild-type ventricles at 5, 
10, and 15 weeks.  D-G, Trichrome 
staining correspondes to the presence 
of collagen I in mdx/utrn-/- cardiac 
muscle.  D, Trichrome staining, image 
taken at 4x magnification.  E-F, Collagen I immunofluorescence (red, Collagen I primary 
antibody with TRITC-conjugated secondary antibody) in an adjacent serial section, G, 
TRITC-secondary antibody-only negative control for collagen staining.  F, G, merged 
images with DAPI for visualizing nuclei.  E-G, 10x  
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Figure 4. Damaged cardiomyocyte membranes and necrosis in cardiac muscle of 15 week old 
mdx/utrn-/- and mdx mice 
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Figure 4. Damaged cardiomyocyte membranes and necrosis in cardiac muscle of 15 
week old mdx/utrn-/- and mdx mice. A-D, Evan’s Blue Dye-positive cells in the mdx/utrn-
/- heart.  A-B, Evan’s Blue Dye-positive cardiomyocytes in the right ventricle 
(arrowheads) and the interventricular septum (arrows).  C-D, Evan’s Blue Dye-positive 
cardiomyocytes in the left ventricle (arrows).  E-F, Evan’s Blue Dye-positive cells in the 
septum of the mdx heart.  A,C, and E, Evan’s Blue Dye, red; wheat germ agglutinin, 
green; B, D, and F are merged images of A, C, and E with DAPI-labeled nuclei, blue, 
respectively.  G, H, Necrosis was detected in mdx/utrn-/- heart (G) but not mdx heart (H) 
at 15 weeks of age with H&E staining.  A-F, yellow arrows indicate chamber of the heart. 
Images for panels A-F acquired at 10x magnification; images for panels G and H 
acquired at 40x magnification.
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Figure 5. Ultrastructure of mdx/utrn-/- cardiac muscle 
 
 
 
 
 
 
 
 
 
 
 
Ultrastructure of mdx/utrn-/- cardiac muscle.  A and B, Mitochondria (M, 
arrowheads) have a regular arrangement in 15 week old wt cardiac muscle between 
fibrils.  C and D, Mitochondria  (M, arrowheads) are disarranged and of varying sizes in 
15 week old mdx/utrn-/- cardiac muscle and the Z-bands are frequently disrupted by the 
irregularly localized mitochondria (arrows).  T, t-tubules.  Magnification, 2000x, A, C; 
10,000x, B, D. 
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Figure 6. Mdx/utrn-/- mice have a similar pattern of cardiac involvement to DMD 
patients.  A comparison of the pathology, and the functional and structural data from the 
current study of the mdx/utrn-/- dystrophin/utrophin-deficient mouse, to reported data 
from Duchenne patients, reveals a similar sequence of events in the development of 
dilated cardiomyopathy.  Mouse age was compared with human age based on Jugdutt et 
al., 2008 (51). CI; cardiac involvement, DCM; dilated cardiomyopathy, EDV; end 
diastolic volume, EF; ejection fraction, FS; fractional shortening, HR; heart rate, LVPW; 
left ventricular posterior wall thickness, LVID; left ventricular internal dimension. 
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Chapter III 
Aorta-derived mesoangioblasts differentiate to cardiomyocytes 
 
A. Introduction 
In DMD contractile movement easily damages cardiomyocyte membrane integrity 
because of the absence of dystrophin. Damaged cell membranes trigger excessive 
extracellular calcium influx [Williams and Allen 2007], calcium related protease activity, 
and eventually induce cardiomyocyte cell death [Raymackers et al. 2003]. This process 
provokes an inflammatory response that leads to fibrosis, affecting the flexibility of 
cardiac muscles during contraction.  This eventually results in development of dilated 
cardiomyopathy (DCM). The combination of cardiomyocyte loss and broad fibrous scar 
areas reduce heart function and recovery is rare. 
As a therapeutic approach to DCM, it is important to replace dead/damaged 
cardiomyocytes and restore electromechanical function. Stem cells have unlimited self-
renewal capacity and multilineage differentiation potency,  which indicate that stem cell 
therapy may be a good mechanism for generating new cardiomyocytes in damaged heart. 
Stem cells have been isolated from different tissues including fertilized eggs: Embryonic 
stem cells from blastocysts, mesenchymal stem cells from bone marrow, adipose and 
umbilical cord, cardiac stem cells from hearts and spermatogonial stem cells from testis. 
These stem cells have differentiated to cardiomyocytes in vitro but rarely in vivo after 
transplantation [Guan et al. 2007, Smith et al. 2007, Van Dijk et al. 2008, Fan et al. 2011, 
Parson et al. 2011, Lin et al. 2012]. Unlike other stem cell types embryonic stem cells 
have been reported to differentiate into cardiomyocytes and are able to contract in vitro 
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and in vivo [Kehat et al. 2001, Laflamme et al. 2007, Yamada et al. 2008]. However 
because of the possible immune rejection and teratoma/teratocarcinoma formation in 
addition to the ethical controversy surroundingdestruction of embryos to abtain them 
embryonic stem cells are not an attractive source of cells therapy. 
Mesoangioblasts are multipotent stem cells, and were derived from embryonic 
dorsal aorta, or adult atria and ventricles of the heart [Galvez et al. 2008]. The cardiac 
mesoangioblasts differentiated to cardiomyocytes with sarcomeric myosin expression, 
and in vitro contractility was also observed following differentiation. The cardiac 
mesoangioblasts also formed new myocardium after intraventricular injection to the 
ischemic heart.   Our lab has derived a similar population of cells, Aorta-derived 
mesoangioblasts (ADM), from postnatal aorta of juvenile mice that are myogenic and 
differentiate into smooth and skeletal muscle cells in vitro and in vitro.  Moreover, after 
transplantation to gastronemius of mdx/utrn-/- mouse model of DMD, ADM were 
incorporated into the damaged skeletal muscles and decreased the number of damaged 
muscle fiber [Berry et al. 2007]. This finding, together with demonstrated cardiac 
differentiation of embryonic mesoangioblasts, supports further studies to determine 
whether myogenic ADM also differentiate to cardiomyocytes. ADM may therefore be 
used to treat two main defects of DMD:  skeletal muscle degeneration and dilated 
cardiomyopathy.  
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B.  Materials and methods 
B-1. Cell culture of mesoangioblasts 
ADM were cultured in Iscove’s Dulbecco Modified Eagle’s minimal essential 
medium (DMEM) containing 20% FBS, 0.1 U/ml penicillin, 0.1 µg/ml streptomycin, 2.0 
mM L-glut, 0.1 mM nonessential amino acids, and minimal essential medium (MEM) 
vitamin solution from Gibco (Carlsbad, CA, USA) and 20 ng/ml purified leukemia 
inhibitory factor (LIF, Chemicon International, Temecula, CA, USA), hereafter referred 
to as ‘proliferation medium’.  The cells were grown on 0.1% gelatin coated plates and 
maintained in a humidified incubator at 37°C in 5% CO2.  
 
B-2. In vitro cardiomyocyte differentiation assay 
ADM were seeded on 0.1% gelatin coated plates with glass coverslips in 
proliferation medium. The 2% horse serum differentiation medium contains 2% horse 
serum in DMEM. The CMGS differentiation medium contains Cardiomyocyte Growth 
Supplement (100X) (ScienCell Research Laboratories, Cat. No. 6252) in 5% FBS 
proliferation medium. The N2B27 differentiation medium contained 10ul/ml NDiff 
Neuro-2 Supplement (200x) (Chemicon, Cat. No. SCM012), 20ul/ml B27 Serum free 
supplement (50x) (Gibco, Cat. No.17504-044) in 4.5g/L glucose DMEM without L-
glutamine (Cellgro, Cat. No. 15-013-CM). Rat primary cardiomyocytes from neonate rat 
heart (ventricle) (ScienCell Research Laboratories, Cat. No. R6200) were used in 5% 
FBS DMEM as a positive control for cardiomyocytes differentiation. Cells were grown 
on 0.1% gelatin coated plates with glass coverslips. The media for each cell type was 
changed every other day. ADM were cultured in differentiation medium for 14 days, and 
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images were acquired every other day. Quantitation of cardiomyocyte differentiation was 
assessed by determining the number of cells in the total population with cardiomyocyte-
like morphology.  
 
B-3. Immunocytochemistry assay 
Cells on glass coverslips were fixed in 3.7% formaldehyde for 10 minutes, and 
blocked in 2% horse serum and 5% BSA for 1 hour. Cardiac differentiation was 
determined by expression of cardiac specific proteins. Mouse monoclonal anti-Troponin I 
(1 to 300 dilution; Millipore Cat. No. MAB1691), sheep polyclonal anti-Tropomyosin (1 
to 300 dilution; Abcam Cat. No. ab5441) and mouse monoclonal anti-actinin (1 to 100 
dilution; Millipore Cat. No. MAB1682) primary antibodies were used. Cells were fixed 
with 3.7% formaldehyde for 10 minutes, and permeabilized with 0.25% Triton X-100 for 
10 minutes at room temperature prior to incubation with primary and secondary antibody. 
Fixed cells were blocked with  2% BSA and 5% horse serum in PBS for 1 hour, 
incubated with primary antibodies for 1 hour at room temperature, washed with 1 X 
phosphate buffered saline, labeled with secondary antibodies (Jackson ImmunoResearch) 
for 1 hour, and mounted with Vectashield mounting medium including DAPI (Vector 
Laboratories, Burlingame, CA).  Rabbit polyclonal anti-Connexin 43 (1 to 300 dilution; 
Sigma Cat. No. C6219) was used for detecting gap junctions. Fluorescent images were 
acquired with a Retiga 200R digital camera (Q-imaging, Surrey, BC) (Nuhsbaum, 
McHenry, IL). Image Pro Plus software (MediaCybernetics, Bethesda, MD) was used to 
assign and merge colors.  
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B-4. RT-PCR analysis 
Expression of cardiac specific transcription factors in ADM after 14 days in 
differentiation medium was detected by RT-PCR. The total RNA from cells grown as a 
monolayer was isolated by Trizol Reagent (Invitrogen, Cat. No. 15596-018), and cDNA 
was synthesized by QIAGEN LongRange 2Step RT-PCR kit (Qiagen, Cat. No. 205920) 
as per the manufacture’s instruction. The primers used in RT-PCR are listed in Table 2. 
 
B-5. Animals 
Mice were cared for according to the Illinois Institutional Animal Care and Use 
Committee guidelines. Mdx/utrn+/- mice were used for generating mdx/utrn-/- mice as 
described in previous studies [Burkin D. J. 2001, Grange R. W. 2002]. After weaning, all 
mdx/utrn-/- mice were placed on the heating pad with moisturized food and extra bedding 
on the cage bottom until they were euthanized.  
 
B-6. GFP transfection of ADM 
For the preparation of GFP labeled ADM, the cells were maintained on gelatin 
coated plates in proliferation medium. The cells were transfected with pIRES2-AcGFP1 
(Clontech, CA, USA) using the LipofectaminTM2000 reagent (Invitrogen, CA, USA), 
according to the product instruction manual. After transfection the cells were cultured in 
proliferation medium with 400mg/ml of G418. The transfected cells were sorted by 
Fluorescence Activated Cell Sorting (FACS) using an iCyte® Automated Imaging 
Cytometer) based on positive GFP signal. Non-transfected control cells were used to set 
the background fluorescence. GFP positive cells were detected by using 520 λ keep the 
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FITC channel, and sorted for purity at 2,000 cells/sec. After sorting, GFP positive cells 
were maintained in proliferation medium with 20 ng/ml LIF and 400mg/ml of G418. 
 
B-7. DiI labeling of ADM 
ADM were incubated with DiI (1,1'-dioctadecyl-3,3,3'3'-
tetramethylindocarbocyanine perchlorate) at a concentration of 1×106 cells/ml with 5µl 
with 5µl DiI/ml in proliferation medium for 30 minutes in a humidified incubator at 37°C 
in 5% CO2 prior to the transplantation. After washing with Hank’s Balanced Salt Solution 
(HBSS) three times, DiI labeled ADM were suspended in HBSS with the concentration 
of 5x106cells/50µl. For double labeling GFP transfected ADM were labeled with DiI 
prior to the transplantation.  
 
B-8. Cardiac injection of ADM 
Mice were anesthetized by halothane (Halocarbon, USA) mixed in mineral oil 
(7.5 ml halothane/40ml of mineral oil). Bactoshield CHG 4% solution (STERIS, MO) 
was used to scrub the anterior chest area of mice. Labeled ADM were transplanted to the 
wall of left ventricle as previously described [Odintsov et al. 2011]. Briefly, insulin 
syringes (3/10 cc with a 29 G needle) with 5x106cells in 50µl HBSS were injected into 
the fifth intercostal space to the left side of the sternum where left ventricular wall is 
located. The plunger was slowly pushed, and  the needle was retracted gently. Following 
injection of cells mice were placed on heating pad and their condition was observed until 
they were fully recovered.  
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C.  Results 
C-1. Aorta-derived mesoangioblasts differentiate to cardiomyocytes in vitro 
The differentiation of ADM to cardiomyocytes was induced with three different 
supplements 1) 2% horse serum 2) cardiomyocyte growth supplement, and 3) N2B27 
serum free supplement. Among them, N2B27 serum free supplement in DMEM was the 
most effective for induction of ADM differentiation to cardiomyocyte based on 
morphological change (data not shown).  ADM in proliferation medium has spindle 
shape (Fig7-A), and has changed its morphology similar to rat cardiomyocyte with a 
large and paper-thin flat cytoplasm in differentiation medium (Fig7-B and C). In addition, 
ADM in differentiation medium made tight contact with adjacent cells, unlike ADM in 
proliferation medium (Fig7-C).  
At day 9 in N2B27 differentiation medium less than 40% of cells had 
cardiomyocyte-like morphology, but nearly all, 97.82%, of cells had cardiomyocytes-like 
morphology at day 14 (Fig10-A). After induction of differentiation to cardiomyocytes, 
we examined ADM for expression of cardiac specific mRNA and proteins. By RT-PCR 
cardiac specific homeobox transcription factor Nkx2.5, cardiac troponin I (cTnI) and 
tropomyosin (cTm) were detected in differentiated ADM (Fig. 8). In addition cTnI, cTm 
and α-actinin proteins were also detected by immunohistochemistry (Fig. 9). At day 14 in 
N2B27 differentiation medium 69% of ADM expressed cTm protein compared to 7% of 
ADM in proliferation medium (Fig10-B).  In addition, connexin 43, a gap junction 
protein was also expressed in the tight contact regions with adjacent cells (Fig9-G).  
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C-2. Aorta-derived mesoangioblasts differentiate into cardiomyocytes in vivo 
To investigate in vivo differentiation, ADM were transplanted into mdx cardiac 
muscle. For tracking transplanted cells, ADM were double labeled with DiI and GFP to 
ensure that cells could still be detected if the DiI label was diluted by cell proliferation. 
First ADM were transfected with GFP. 96.33% of cells (Fig. 11) were GFP positive 
which were labeled with DiI prior to the transplantation. Cells co-labeled with both GFP 
and DiI were localized in the ventricles of the heart (Fig. 12).  After verifying that DiI 
was not lost from ADM after injection due to co-localization of both labels in cells, ADM 
were singly labeled with DiI for subsequent experiments. ADM silenced GFP expression 
over time, and that GFP prevent ADM differentiation into some mature cell types after 
transfection with GFP (data not shown). 
 To determine whether the transplanted ADM differentiated into cardiomyocytes, 
immunohistochemistry was performed using an antibody to cardiac troponin I (cTnI), 
marker of cardiomyocytes (Fig. 13-A). DiI positive cells co-localized with cTnI positive 
labeling, indicating that the donor ADM expressed cTnI 6 weeks after injection into the 
heart (Fig13-B-C).  
 Next, immunostaining was used to examine whether dystrophin was restored in 
cardiac muscle of mdx mice after ADM transplantation. Dystrophin was detected in the 
specific pattern around the cytoplasm in longitudinal and cross sections of muscle tissue 
from the ventricles (Fig. 14).  DiI particles were detected in the cytoplasm of cardiac 
myocytes positive for dystrophin staining.  These data confirm that ADM express 
dystrophin in the heart after injection, indicating that the stem cells have differentiated 
into muscle cells in vivo. However the intensity of detected dystrophin was weaker than 
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wild type positive control and dystrophin was detected in only limited regions of the heart 
rather than throughout the entire ventricle.  
 
D.  Discussion   
Because of the absence of dystrophin, cardiomyocytes in DMD are exposed to the 
continuous damage by mechanical stress, which will eventually induce the death of 
cardiomyocytes. Unfortunately hearts rapidly lose their regenerative ability after birth, 
and leave little option for treatment following damage except heart transplantation 
[Bergmann et al. 2009]. Cell therapy with transplantation of exogenous stem cells is 
currently being investigated for the treatment of damaged cardiac muscles. Although 
multiple types of stem cell have been tested for regeneration of skeletal muscle in DMD 
animal models and DMD patients, few have been tested for treatment of dilated 
cardiomyopathy in DMD.  
First, ADM were induced to differentiate to cardiomyocytes in three different 
medium conditions; 2% horse serum, cardiomyocytes growth supplement, and N2B27, 
Cardiomyocyte-like cells with a flat and thin cytoplasm were detected in all three 
medium conditions, although the serum free condition showed the most dramatic result.  
In N2B27 differentiation medium most of ADM changed their morphology to 
cardiomyocyte-like in 14 days and expressed cardiac specific cDNAs (Nkx2.5, cTnI and 
cTm) and proteins (cTnI, cTm and α-actinin). We did not expect ADM to differentiate 
into cardiac-like cells in this medium condition because N2 and B27 supplements were 
formulated for the growth of rat neuroblastoma cells and survival of hippocampal 
neurons in a serum free culture system [Bottenstein et al.1979, Brewer et al. 1993]. 
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However, cardiomyogenic differentiation may share some common molecular players 
and pathways  with neuronal differentiation during embryogenesis. Murashov et al. 
induced cardiomyocyte differentiation by neuronal differentiation medium [Murashov et 
al. 2004], and also reported that embryonic stem cells differentiated to functional 
cardiomyocytes with neuronal cells in aggregation [Murashove et al. 2005]. In addition a 
transcription factor, serum response factor (SRF) is involved in cardiomyocyte 
differentiation [Zhao et al. 2005] and also in the central nervous system [Stringer et al. 
2002]. These data offer an explanation and precedent for our observations of efficient 
ADM differentiation to cardiomyocytes in the medium with N2B27 neuronal 
supplements.  
Connexin 43 is a predominant gap junction molecule in the heart, which serves to 
electrically couple cardiomyocytes in the heart, allowing the heart to maintain a rhythm 
during contraction. In the differentiation medium, ADM formed tight contact with 
adjacent cells and expressed connexin 43 at the junctions. Connexin 43 expression by 
ADM strongly supports the possibility that these cells would be a good stem cell source 
that would functionally integrate with cardiomyocytes in vivo to provide functional 
benefit. 
GFP and DiI positive cells were found to co-localize in the heart 3 weeks after 
transplantation. DiI co-localized with cTnI in cells in the ventricle of the heart. These 
data indicate that ADM express cardiac-specific markers up to 6 weeks following 
transplantation, indicating that the cells survive and differentiate into cardiomyocytes.  
ADM may therefore be used to replace damaged/dead cardiomyocytes.  Modest 
dystrophin expression was detected in the heart after injection of ADM, and co-localized 
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to DiI positive cells in the left ventricle.  This indicates that injected ADM may 
differentiate to cardiomyocytes and restore dystrophin expression in dystrophic hearts.  
For regeneration of cardiac muscles in patients with DMD there are two main 
aspects to be considered. First damaged cardiomyocytes must be replaced/regenerated to 
recover heart function. Second, cardiac muscle needs to be protected from further damage 
by contractile stress, for example, through restoring dystrophin. In this regard stem cells 
carrying a full-length dystrophin gene for therapeutic application in DMD are strongly 
suggested to study their capability of cardiomyocytes differentiation and dystrophin 
restoration in vitro and in vivo. With this, in this study ADM has been tested its 
differentiation ability to cardiomyocytes and restore dystrophin in dystrophic hearts.   
 
 
 
. 
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Figure 7. Induction of ADM differentiation into cardiomyocytes in vitro 
 
 
Induction of ADM differentiation into cardiomyocytes in vitro. ADM in 
proliferation medium (A), primary rat cardiomyocytes (B) and ADM in differentiation 
medium with N2B27 (C). 
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Figure 8. ADM express cardiac specific mRNA 
 
 
 
 
 
 
ADM express cardiac specific mRNA. Heart: tissue from cardiac muscle was 
used as a positive control from heart tissues, Adipose was used as a negative control for 
cardiac markers, HS: horse serum, CMGS: cardiomyocyte growth supplement, GAPDH: 
an internal loading control. cTnI: cardiac troponin I, cTm: cardiac tropomyosin 
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Figure 9. Cardiac specific protein expression in ADM 
 
Cardiac specific protein expression in ADM. Primary rat cardiomyocytes were 
used as a positive control for cardiac proteins (A-C), ADM in differentiation medium also 
express cardiac markers (D-F), cardiac tropomyosin (A and D), cardiac troponin I (B and 
E), alpha-actinin (C and F), connexin 43 (G), Blue: DAPI.  
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Figure 10. Quantitative analysis of ADM cardiac differentiation in vitro 
 
 
 
 
 
 
 
 
 
 
 
 
Quantitative analysis of ADM cardiac ifferentiation in vitro. Cardiac 
morphological change (A) and cardiac tropomyosin expression (B) of ADM in 
differentiation medium with N2B27 supplements. 
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Figure 11. pIRES2-AcGFP1 transfection and characterized by Fluorescent Activated 
Cell Sorting (FACS) of ADM. Untransfected cells were used as a negative control (A), 
ADM expressing GFP were sorted with FACS (B), and observed using fluorescence 
microscopy (C). 
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Figure 12. ADM are detected in vivo using GFP and DiI after transplantation to mdx heart 
 
 
 
 
 
 
 
 
 
 
Using GFP and DiI labeling were used to track ADM after transplantation into 
mdx heart. DiI (A), GFP (B), DiI with DAPI (C) and GFP with DAPI (D).  
 
 
  57 
 
 
Figure 13. DiI labeled ADM express cardiac markers after transplantation to the heart of mdx  
 mice 
 
DiI-labeled ADM express cardiac marker after transplantation to the heart of mdx 
mice. Cardiomyocytes co-localized with DiI in heart section were after DiI labeled ADM 
transplantation to the heart of mdx mice. Cardiac troponin I (green) with DAPI (A), DiI 
(red) with DAPI (B), cardiac troponin I positive cells with DiI and DAPI (C), and 
secondary (FITC) antibody negative control (D). 
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Figure 14. DiI labeled ADM exhibit dystrophin expression in the heart of mdx mice 
 
DiI-labeled ADM exhibit dystrophin expression in the heart of mdx mice. 
Dystrophin (green) with DiI (red) (A) and dystrophin co-localized with DiI and DAPI in 
longitudinal heart section (B), and dystrophin with DiI (C) and dystrophin co-localized 
with DiI with DAPI D) in heart cross section. 
 
 
 
  59 
 
Table 2. Primer sequences for RT-PCR. 
 
Genes Size Primer sequences 
Tropomyosin 855 bp Forward: 5’- CAG AAG GCA AAT GTG CCG AG -3’ 
  Reverse: 5’- TCC AGC ATC TGG TGC ATA CTA -3’ 
Troponin I 564 bp Forward: 5’- ATG CCG GAA GTT GAG AGG AAA -3’ 
  Reverse: 5’- TCC GAG AGG TAA CGC ACC TT -3’ 
Nkx 2.5 100 bp Forward: 5’- CGG AAC GAC’ TCC CAC CTT TAG -3’ 
  Reverse: 5’- TGG GAT GGA TCG GAG AAA GG -3’ 
GAPDH 150 bp Forward: 5’- CAT CCT GCA CCA CCA ACT GC -3’ 
  Reverse: 5’- ACG CCA CAG CTT TCC AGA GG -3’ 
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Chapter IV 
Injection of vessel derived stem cells-prevents onset of dilated cardiomyopathy in 
mdx/utrn-/- dystrophin/utrophin-deficient mice but fails to improve pre-existing dilated 
cardiomyopathy in aged mdx mice 
 
A.  Introduction 
Cardiac involvement in Duchenne muscular dystrophy (DMD) is covert, unlike 
severe skeletal muscle defects observed in this disease, and patients often exhibit an 
advanced stage of dilated cardiomyopathy when it is diagnosed. Approximately 90% of 
patients are diagnosed with cardiomyopathy and 25% of them exhibit pre-clinical cardiac 
involvement by 6 years of age. 20~40% of patients die because of cardiomyopathy by 
their third decade of life. [Nigro et al. 1990, Bushby et al. 2003, Baxter et al. 2006].   
In the past decade, medical advances have been developed that extend the lifespan 
of DMD patients from their early teens into their early 30s.  As disease progression 
continues over this time, an increase in the incidence of cardiac dysfunction has been 
observed [Kamogawa et al. 2001, Eagle et al. 2002, Eagle et al. 2007].  This underscores 
the importance of finding a method to treat cardiomyopathy in these patients [Townsand 
et al. 2009]. As a result, follow-up monitoring for the development of cardiomyopathy 
has been recommended for patients after a diagnosis of DMD, to allow management of 
progressing cardiomyopathy [Ahuja et al. 2000, Bouhouch et al. 2008]. In this regard it is 
important to investigate the effect of candidate treatments of DCM in DMD during 
different stages of disease in the heart.  
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For treatment of dilated cardiomyopathy in DMD there are two aspects of 
concern: 1) replacing damaged/dead cardiomyocytes and 2) restoring dystrophin 
expression. The absence of dystrophin leads to loss of cell membrane integrity and 
eventually to cell death. For recovering cardiac function it is important to replace 
damaged/dead cardiomyocytes.  Hearts have limited regeneration capacity from 
endogenous cardiomyocytes. Transplantation of exogenous stem cells with a normal copy 
of the dystrophin gene might contribute to replace damaged/dead cardiomyocytes and 
restoration of dystrophin in hearts with non-functional dystrophin. However, simply 
replacing cardiomyocytes is not sufficient.  Because cardiac myocytes that do not express 
dystrophin are continuously exposed to damage from mechanical stress during 
contraction, restoration of dystrophin is also essential for protecting cardiac muscles from 
further damage.  
We isolated ADM from aortas of 1~3 day old wild type C57BL10 mice and 
confirmed that they differentiate into cardiomyocytes with cardiac specific gene and 
protein expression in vitro and in vivo. ADM transplantation also restored dystrophin 
expression in the heart of mdx mice (Fig. 14).  Moreover ADM might functionally 
cooperate with resident cardiac myocytes because in vitro studies indicate that ADM 
express a gap junction molecule, connexin 43, which allows electrical coupling of 
cardiomyocytes for contraction in cardiac muscle.  All of these characteristics indicate 
that ADM may be useful for treating cardiomyopathy in DMD.  Here I hypothesized 
that ADM transplantation would restore dystrophin expression, and prevent dilated 
cardiomyopathy in dystrophic heart of murine models of DMD.   
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In this study two different DMD animal models were used: mdx and mdx/utrn-/- 
mice. Mdx develop dilated cardiomyopathy at 12-21 months of age, and mdx/utrn-/- mice 
develop dilated cardiomyopathy at 10 to 15 weeks of age [Chun et al. 2012]. Using these 
two murine models, I have determined that ADM transplantation does not ameliorate 
dilated cardiomyopathy (mdx mice) but that it does prevent or delay the development of 
cardiomyopathy (mdx/utrn-/- mice) in dystrophic heart.  
 
B.  Materials and methods 
B-1. Animal care.   
All animal use was approved by the University of Illinois Institutional Animal 
Care and Use Committee. Mdx/utrn−/− mice were generated by mating mdx/utrn+/− male 
and female mice [Grady et al. 1997], and the progeny were genotyped as previously 
described [Burkin et al. 2001, Grange et al 2002]. As a control group age-matched wild-
type mice were used for comparison in all experiments. After intramyocardiac injection 
all mice were placed on a heating pad until they were fully recovered. Mdx/utrn-/- mice in 
cages were placed on a heating pad with moisturized food for the duration of the 
experiment until euthanization. 
 
B-2. Echocardiography 
Two-dimensional M-mode echocardiography was used to measure heart function. 
A baseline echocardiograph was performed on 5 week old mdx/utrn-/- mice and 14~16 
month old mdx mice prior to cell transplantation. Echocardiography was performed once 
again 5 weeks after cell transplantation in mdx/utrn-/- mice and 10 weeks after cell 
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transplantation in mdx mice. GE/Vingmed ultrasound Vivid7 (GE healthcare) was used 
for performing echocardiograph with mdx mice, and Ultrasound-Visual Sonics Vevo 
2100 (Visualsonics, Toronro, Canada) was used for performing echocardiograph with 
mdx/utrn-/- mice. Mice were anesthetized by halothane in mineral oil as described above. 
The chest hairs were clipped, ultrasound gel was placed on the transducer, the transducer 
was placed on top of the chest, and images were acquired. Mdx and mdx/utrn-/- mice were 
presented with age matched wild type mice randomly to the echocardiographer, who was 
blinded to the genotype of mice.  
 
B-3. Statistics 
The Proc Mixed procedure of SAS (SAS Inst. Inc., Cary, NC) was used to analyze 
the echocardiograph data. The statistical model included effects of genotype, ages, time 
point of performing echocardiographs, and their interaction as fixed effects. Differences 
between before and after cell transplantation within each genotype and among genotypes 
within each time point of performing echocardiography were tested by pair-wise 
comparisons when the main effects were significant.  
 
B-4. Cell Culture 
ADM were grown on 0.1% gelatin coated plates in Iscove’s Dulbecco Modified 
Eagle’s minimal essential medium (DMEM) containing 20% FBS, 0.1 U/ml penicillin, 
0.1 µg/ml streptomycin, 2.0 mM L-glut, 0.1 mM nonessential amino acids, and minimal 
essential medium (MEM) vitamin solution from Gibco (Carlsbad, CA, USA) and 20 
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ng/ml purified leukemia inhibitory factor (LIF, Chemicon International, Temecula, CA, 
USA). The cells were maintained in a humidified incubator at 37°C in 5% CO2.  
 
B-5. Labeling and injection of stem cells 
Prior to the transplantation ADM were incubated with  5 µl of DiI (1,1'-
dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate) at density of 1 million 
cells per 1 ml of proliferation medium for 30 minutes in a humidified incubator at 37°C 
in 5% CO2.  DiI labeled ADM were washed with Hank’s Balanced Salt Solution (HBSS) 
three times and suspended in HBSS at a concentration of 5x106cells/50µl.  
 
B-6. Cardiac injection of ADM 
Mice were anesthetized by halothane (Halocarbon, USA) mixed in mineral oil 
(7.5 ml halothane/40ml of mineral oil). Bactoshield CHG 4% solution (STERIS, MO) 
was used to scrub the anterior chest area of mice. Intramyocardiac injection was 
performed in the wall of the left ventricle as previously described [Odintsov et al. 2011]. 
Briefly, insulin syringes (3/10 cc with a 29 G needle) with 5x106cells in 50µl HBSS or 
50µl HBSS without ADM were injected into the fifth intercostal space to the left side of 
the sternum where the left ventricular wall is located, the plunger was slowly pushed, and  
needle was retracted gently. After cell injection mice were placed on a heating pad and 
their condition was observed until fully recovered.  
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B-7. Western blot 
Protein samples were prepared from frozen heart with 15~20 sections with 10 µm 
thickness per sample. Briefly frozen heart sections were collected in an eppendorf tube 
and lysed in 2X SDS buffer (10%SDS, 100 mM Tris-HCl (pH8.0), 10mM EDTA, 10 % 
glycerol, 1µg/ml Aprotinin and 100 µg/ml PMSF), boiled at 100 °C for 10 minutes, 
centrifuged 10,000 rpm for 10 minutes, and supernatants were collected and stored at -80 
°C for further Western blotting assays. 40 µg of protein sample was used for Western 
analysis. Whole protein lysate was separated by a SDS-polyacrylamide gel composed 
with 5 and 10 % polyacrylamide for 1.5 hours at 150V. Proteins were transferred to a 
PVDF membrane at 0.05A  overnight at 4°C. After blocking in 5% non-fat dry milk in 
1X TBST the membrane was incubated with rabbit polyclonal anti dystrophin antibody (1 
to 1,000 dilution; Abcam, Cat. No. ab15277) overnight at 4 °C, and with anti-rabbit IgG 
HRP-linked antibody (1 to 500 dilution; Cell Signaling, Cat. No. 7074) for 1 hour at 
room temperature. The target protein was visualized with SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific, Cat. No. 4077) on X-ray film (Denville 
Scientific Inc., Cat. No. E3018). GAPDH was used as a loading control.  GAPDH 
antibody (Sigma, Cat. No. G9545) was used at a concentration of 1:1,000. 
 
B-8. Immunohistochemistry assay 
After a second echocardiograph, mice were euthanized by CO2, and hearts were 
isolated and weighed. Hearts were frozen in liquid nitrogen-cooled 2-methylbutane, and 
stored -80 °C. Frozen hearts were sectioned at 10 µm, and tissue sections were fixed prior 
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to incubation with 2% horse serum and 1% BSA blocking solution in PBS. (Primary 
antibodies used are listed in Table 3)  
 
B-9. Data Analysis   
For digital images a Retiga 2000R digital camera (Q-imaging, Surrey, BC) was 
used with a Leica Inverted DMI 4000B microscope (Nuhsbaum, McHenry, IL). Images 
were assigned color and merged using Image Pro Plus software (MediaCybernetics, 
Bethesda, MD), which was also used for counting and measuring primary antibody 
stained positive areas.  The average of each protein expression was counted based on the 
positive area or cell number on sections, and divided by whole area of same section or 
whole cell number in the same section.  
 
C.  Results 
C-1. Echocardiography of mdx/utrn-/- mice with ADM transplantation 
Echocardiography was performed before and after ADM transplantation and 
resulting data compared to study the changes related to stem cell transplantation. Age-
matched wild type mice and mdx/utrn-/- mice were used as control groups (Table 4).  
Thinning of the septum was observed in both mdx/utrn-/- mice injected with saline and 
mdx/utrn-/- mice injected with ADM (Table 16 and Fig. 6). However, the left ventricle 
was enlarged, characteristic of dilated cardiomyopathy, only in mdx/utrn-/-  mice injected 
with saline solution.  LVIDd and LVID significantly increased in mdx/utrn-/-  mice 
injected with saline solution, but not in wild type mice with saline injection and mdx/utrn-
/-  mice injected with saline solution, in which the LVIDs decreased following stem cell 
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injection (Fig. 17).  The wall of the left ventricle also became significantly thinner in 
mdx/utrn-/-  mice injected with saline solution. LVPW was significantly decreased in 
mdx/utrn-/-  mice injected with saline solution, but mdx/utrn-/-  mice injected with ADM 
had significantly increased LVPWs (Fig. 18). However EDV was significantly increased, 
also characteristic of dilated cardiomyopathy, in mdx/utrn-/-  mice injected with saline 
solution (Fig. 19). Overall, wild type mice with saline injection showed no change except 
decreased LVID at systole.  
 
C-2. Effect of ADM on extracellular remodeling and cardiac fibroblasts in 
mdx/utrn-/- mice 
Collagen I has important roles regarding the structural and functional integrity of 
heart. Excessive accumulation of collagen I is related to fibrosis formation and 
development of dilated cardiomyopathy. For detecting fibrotic tissues anti-collagen I 
antibody was used. There was no significant difference in collagen content between 
mdx/utrn-/- mice with saline injection or with stem cell injection.  The collagen receptor 
Discoidin Domain Receptor 2 (DDR2) is a specific marker for cardiac fibroblasts 
[Goldsmith et al., 2004], which produce collagens [Eghmali et al. 1988, Chapman et al. 
1990]. Anti-DDR2 antibody was used to detect cardiac fibroblast which is related to the 
expression of collagen I. There was no significant difference in the number of DDR2 
cells in mdx/utrn-/- mice injected with saline or ADM (Fig. 25), but there is higher 
number of DDR2 positive cells in wild type control mice compared to mdx/utrn-/- mice 
(Fig. 25).  
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C-3. Effect of ADM on expression of a vascular adhesion molecule in mdx/utrn-/- 
mice 
CD31, also known as platelet endothelial cell adhesion molecule (PECAM-1), is 
involved in angiogenesis and expressed by endothelial cells [Albelda et al. 1991, 
Newman et al., 1997]. CD31 expression was used to assess whether there was a change in 
vasculature of the heart after ADM transplantation (Fig. 28). The expression of CD31 
was significantly higher in mdx/utrn-/- mice with ADM injection compared to the 
mdx/utrn-/- mice with saline injection (Fig. 29). Interestingly the CD31 expression in 
mdx/utrn-/- mice with ADM injection was even higher than in age-matched wild type 
control mice (Fig. 29-A).  No significant difference in CD31 expression was observed in 
wild type control mice or mdx/utrn-/- mice injected with saline injection (Fig. 29-A).  
 
C-4.  Effect of ADM on  proliferating cells in mdx/utrn-/- mice 
Ki-67 is a nuclear protein which is associated with cellular proliferation and is 
present during interphase of cell cycle (G1, S, G2, and mitosis). For detection of 
proliferating cells in the heart, anti-Ki-67 antibody was used. The number of Ki-67 
positive cells was not statistically different between mdx/utrn-/- mice with saline 
injection and ADM injection (Fig. 27-A).  However there was a statistical tendency 
(p<0.06) toward an increase in the number of Ki-67 positive cells in mdx/utrn-/- mice 
injected with ADM, but not following injection of saline (Fig. 27-A). 
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 C-5. Effect of ADM on expression of connexin 43 in mdx/utrn-/- mice 
In heart, electrical cell-cell communication between cardiomyocytes is achieved 
through gap junctions. Connexin 43 is the most abundant type of gap junction molecule 
in cardiac muscle [Beyer et al. 1989].  Connexin 43 was measured but was not different 
between mdx/utrn-/- mice injected with saline or ADM (Fig. 30). However more connexin 
43 was expressed in wild type control mice (Fig. 31).   
 
C-6. Effect of ADM on dilated cardiomyopathy in mdx mice 
Echocardiography was performed before ADM transplantation and at 10 weeks 
after ADM transplantation. Echocardiograph data were compared to study the changes of 
cardiac morphology and function related to ADM transplantation. Aged–matched wild 
type mice and mdx mice with saline injection were used as control groups (Table 4). 
Interventricular Septum (IVS) at systole was significantly decreased in wild type with 
saline injection and mdx with saline injection, but not in mdx with ADM injection. IVS at 
diastole decreased in all groups (wt/HBSS, mdx/HBSS and mdx/ADM) (Table 4). Left 
LVID was significantly enlarged in mdx with ADM injection but not in wild type with 
saline injection and mdx with saline injection (Fig. 33). LVPW was significantly 
decreased in mdx with saline injection but it was notably increased in mdx with ADM 
injection (Fig. 34). As functional parameters EF and FS were significantly decreased in 
both mdx with saline injection and mdx with ADM injection (Fig. 35 and Fig. 36). 
However, only mdx with ADM injection displayed a significant increase with EDV and 
ESV (Fig. 37 and Table 4). 
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C-7. Effect of ADM on extracellular remodeling and cardiac fibroblasts in mdx 
mice  
Higher collagen I expression was detected in mdx mice injected with either ADM 
or saline injection in comparison to age matched wild type controls (Fig. 38 and Fig. 39). 
However there was no significant difference in collagen content with stem cell injection 
between mdx with ADM injection and mdx with saline injection (Fig. 39).  The collagen 
receptor Discoidin Domain Receptor 2 (DDR2) is a specific marker for cardiac 
fibroblasts [Goldsmith et al. 2004], which produce collagen [Eghmali et al. 1988, 
Chapman et al. 1990]. There was no significant difference in numbers of DDR2 cells 
between mdx mice injected with saline or ADM (Fig. 40 and 41). Interestingly higher 
levels of collagen I were detected  in both groups of mdx mice than in wild type with 
saline injection although there was no difference in numbers of DDR2 positive cells 
among wild type with saline injection, mdx with saline injection and mdx with ADM 
injection(Fig 41).  
 
C-8. Effect of ADM on expression of a vascular adhesion molecule in mdx mice 
Anti-CD31 antibody was used to detect the vasculature in the heart to determine 
whether ADM transplantation altered this parameter. CD31 positive areas were 
measured, and the average was calculated (Fig. 44 and 45).  There was no significant 
difference in CD31 expression among mdx with saline injection and mdx with ADM 
injection including wild type mice with saline injection (Fig. 45). 
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C-9.  Effect of ADM on proliferating cells  in the mdx heart  
 Compared to wild type mice with saline injection there were significantly fewer 
Ki-67 positive cells in mdx mice injected with saline and mdx mice injected with ADM 
(Fig. 43). However, there was no statistical difference in the number of Ki67 positive 
cells between mdx injected with saline and mdx injected with ADM.  
 
C-10. Effect of ADM on expression of connexin 43 in mdx mice 
To determine whether gap junctions were altered during disease progression or 
following ADM injection, expression of connexin 43, a gap junction protein, was 
examined (Fig. 46). There was no significant difference in expression of connexin 43 
among wild type mice injected with saline injection, mdx with injected with saline or 
mdx mice injected with ADM (Fig. 47). However there was slight tendency ( p<0.07) 
towards an increase in mdx mice injected with ADM in comparison to mdx mice injected 
with saline (Fig. 47-A).  
 
C-11. Restoration of dystrophin after ADM transplantation in mdx/utrn-/- and mdx 
mice 
Dystrophin was detected in the heart of mdx and mdx/utrn-/- mice after ADM 
injection. In mdx/utrn-/- mice with ADM injection, restored dystrophin was detected (Fig. 
47) by immunohistochemistry, but not detected by western blot (Fig. 48). There were two 
different expression patterns of restored dystrophin (Fig. 47-A-F) in 
immunohistochemistry. The pattern in relatively larger areas consisted of weak 
dystrophin positive signal throughout(Fig. 47-C-D and E-F), although a different pattern, 
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including strong dystrophin positive staining, was present around individual cells in small 
regions (Fig. 47).  However restored dystrophin was found in limited areas rather than in 
all heart sections. In mdx mice with ADM transplantation we did not detect dystrophin 
expression.  
 
D.  Discussion 
As we previously reported, at the age of 5 weeks, when ADM were injected, 
mdx/utrn-/- mice showed no sign of cardiomyopathy [Chun et al. 2012]. However at 10 
weeks of age, thinning of the IVS and LVPW, as well as enlarged LVID, was observed in 
mdx/utrn-/- mice injected with saline. This is also similar to our previous report, as dilated 
cardiomyopathy is beginning to develop at this time [Chun et al. 2012].  In contrast, 
mdx/utrn-/- mice injected with ADM did not exhibit thinning of the ventricle wall or an 
enlarged chamber (Fig. 16 and 18). There were no significant changes in EF and FS in all 
groups (Fig. 20 and 21). However a significant increase in EDV was detected in 
mdx/utrn-/- mice injected with ADM (Fig. 19).  That is, mdx/utrn-/- mice injected with 
ADM experienced improvement in systolic function based on IVSs, LVPWs and LVIDs 
and remained healthy without developing left ventricular dilation. In summary ADM 
transplantation to hearts prevent development of dilated cardiomyopathy in mdx/utrn-/- 
mice with systolic functional improvement. 
To determine why ADM may prevent delay cardiomyopathy in mdx/utrn-/- mice, 
we examined the heart of mice to determine whether pathology was decreased after stem 
cell injection. Fibrosis formation in mdx/utrn-/- heart was measured by assessing collagen 
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I. There was significantly more collagen I in the heart of wild type control mice than in 
either mdx/utrn-/- mice injected with saline or injected with ADM (Fig. 23-A). However, 
there was no difference in collagen content between mdx/utrn-/- mice injected with saline 
or ADM (Fig. 23). Similarly, there was no difference in the number of DDR2 positive 
fibroblasts between mdx/utrn-/- mice injected with saline or ADM, and both groups have 
fewer DDR2 positive cells compared to wild type control mice (Fig. 25).  These data 
demonstrate that the collagen content and cardiac fibroblasts vary with genotype, but are 
not altered by stem cell injection. The fibrillar collagen network is an important 
component of the extracellular matrix and disruption of this network induces structural 
cardiac remodeling which is related to declining cardiac function [Spinale 2007, Fedak et 
al. 2008]. The reduced collagen I expression in mdx/utrn-/- mice in comparison to wild 
type mice may reflect an abnormal collagen network caused by absence of dystrophin.   
It is possible that the injected stem cells differentiate into cardiomyocytes 
therefore inducing functional benefit in mdx/utrn-/- mice. High levels of red auto 
fluorescence, particularly in aged mdx heart, hampered detection of DiI-labeled donor 
cells.  As a result, no DiI positive cells were detected in mdx heart injected with ADM, 
and donor cells were positively identified in only one mdx/utrn-/- mice heart injected with 
donor cells. We therefore were not able to examine the fate of donor cells in the heart. 
However, the presence of dystrophin in the heart of mdx/utrn-/- mice injected with ADM 
is indicative of donor cell differentiation into cardiomyocytes (Fig. 47). 
The heart of mdx/utrn-/- mice was also examined for indirect effects from ADM 
injection.  There was also no statistically significant difference in the number of Ki-67 
positive cells between mdx/utrn-/- mice injected with saline and mdx/utrn-/- mice injected 
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with ADM, and there was also significantly less proliferating cells in both groups than in 
wild type control mice (Fig. 27). However there was a slight statistical trend (p<0.07) of 
greater numbers of Ki67 positive proliferating cells in mdx/utrn-/- mice injected with 
ADM in comparison to mdx/utrn-/- mice injected with saline.  It is likely that this trend 
was not statistically significant because of the large variation among individual mice in 
the different treatment groups.  To determine whether this trend is significant, increased 
number of mdx/utrn-/- mice should be examined. The number of proliferating cells in 
mdx/utrn-/- heart with ADM injection is similar to wild type mice with saline injection 
(Fig. 27-A).  An increase in Ki67 positive cells with ADM injection may indicate that the 
increased proliferating cells are contributing to regenerate damaged cardiac muscles.  
Angiogenesis is a well-known indirect effect of stem cell therapy known to 
improve heart function. It has been reported that angiogenesis facilitates regeneration of 
damaged tissues with stem cell transplantation [Zhang et al. 2010, Katare et al. 2011]. To 
determine whether ADM may prevent heart dysfunction by enhancing blood flow to the 
heart, we examined the vasculature in the heart of mdx/utrn-/- mice. Mdx/utrn-/- hearts 
injected with ADM had  more CD31 positive staining compared to the hearts of age-
matched wild type control mice and mdx/utrn-/- heart injected with saline, indicating that 
ADM may stimulate angiogenesis in the heart after transplantation (Fig. 28 and 29). 
Therefore angiogenesis could be the reason why there was cardiac functional benefit by 
ADM transplantation together with increased number of proliferating cells in mdx/utrn-/- 
mice. 
Interestingly in mdx/utrn-/- heart injected with ADM restored dystrophin was 
detected with immunohistochemistry (Fig. 48) but not with western blotting (Fig. 49).  
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This may indicate that the amount of restored dystrophin is too small to be detected by 
Western analysis, or that protein degradation might occur during frozen section 
preparation for western blotting. In agreement with this, dystrophin staining detected with 
immunohistochemistry was faint (Fig. 47) in many regions, although in some areas a 
small number of intensely stained cells were also detected (Fig. 47-C and D). This low 
level of restored dystrophin may contribute to the functional benefit on mdx/utrn-/- mice, 
however, as previous studies have shown functional benefit from restoration dystrophin 
to 30% of wild-type levels [Wu et al. 2010, Van Putten et al. 2012]. 
In contrast to mdx/utrn-/- mice, injection of stem cells into the heart of mdx mice 
with existing cardiomyopathy does not result in functional benefit. Mdx mice have 
dilated cardiomyopathy by 10~12 months of age that is similar to patients with DMD, 
including  excessive fibrosis formation  and decreased cardiac function similar to the 
patients with DMD [Quinlan et al. 2003, Spurney et al. 2008, Bostick et al. 2008, Van 
Erp et al. 2010]. Based on these reports, we injected ADM into 14-16 month old mdx 
mice.  IVS and LVPW became thinner in mdx mice after saline injection and the EF and 
FS were also significantly decreased 10 weeks after HBSS cardiac injection, indicating 
that mdx mice were developing progressive dilated cardiomyopathy with aging. A 
significantly enlarged LVID, increased EDV and ESV, and decreased EF and FS with 
thickened LVPW were detected in mdx mice injected with ADM. From this finding, 
there was no beneficial effect by ADM transplantation in cardiac function of mdx mice 
which have dilated cardiomyopathy, and in fact the cells exacerbated the condition.  
Fibrosis is one of the well-known characteristics of dilated cardiomyopathy in 
patients with DMD. There is more collagen I detected in mdx heart injected with saline 
  76 
than age-matched wild type mice, similar to reports in previous studies [Quinlan et al. 
2003, Bostick et al. 2008, Spurney et al. 2008, Erp et al. 2010]. Cardiac fibroblasts are 
involved in production of collagen [Eghmali et al. 1988, Chapman et al. 1990], and it was 
assumed that collagen I expression is in proportion as DDR2 expression.  However there 
was a decrease in the number of DDR2 positive cells in mdx mice in comparison to age-
matched wild type mice, although the collagen I content of the mdx heart was higher in 
comparison to age-matched wild type controls. It has been reported that collagen extracts 
from aged mice have a decreased diameter and density of collagen fibrils with loosened 
collagen network [Damodarasamy et al. 2010]. Collagen I in aged mdx mice may 
therefore be expressed in relatively larger areas because of loosened collagen network 
with less density.  
Hearts of mdx mice were studied for indirect effects from ADM transplantation 
including proliferation, angiogenesis and gap junction formation. There were 
significantly lower numbers of Ki-67 positive cells in both mdx mice injected with saline 
or with ADM compared to age-matched wild type controls, but there was no difference 
between mdx mice injected with saline and mdx mice injected with ADM, indicating that 
there was no effect of ADM transplantation on overall cell proliferation. There was no 
difference of CD31 expression among mdx with saline injection and mdx with ADM 
injection including wild type with saline injection. There was also no significant effect of 
donor cell injection on the gap junction protein, connexin 43 compared to wild type 
control mice, and also no significant difference between mdx mice with saline injection 
and mdx with ADM injection. However there was a tendency towards higher connexin 43 
expression in the mdx with ADM injection group in comparison to the mdx with saline 
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injection group (p<0.08; Fig. 47-A). Together, ADM transplantation into mdx heart after 
onset of dilated cardiomyopathy and fibrosis resulted in no detectable indirect effect on 
endogenous regeneration. There was also likely no direct differentiation of ADM into 
cardiomyocytes, as no dystrophin protein was detected by either immunohistochemistry 
or western blotting assay (Fig. 48 and 49). These results are unexpected because we 
found cardiac specific protein was co-localized with DiI labeled ADM and restored 
dystrophin expression after transplantation into mdx heart in Chapter III. Unlike the 
young mdx mice which were used in Chapter III, aged mdx mice have severe dilated 
cardiomypathic heart. It could be an influence of the different microenvironment present 
in the disease condition, related to ages of mdx mice, that influences the direct 
differentiation of ADM into cardiomyocytes. 
In stem cell therapy there are two main ways that stem cells may improve 
function of damaged cardiac muscles: 1) by direct differentiation to cardiomyocyte, and 2) 
from indirect mechanisms such as release of paracrine factors like vascular endothelial 
growth factor (VEGF) and fibroblasts growth factor (FGF). Multiple types of stem cells 
which promote functional benefit in damaged heart differentiate to cardiomyocytes, 
including skeletal muscle derived stem cells (SMDS), cardiac stem cells (CSC), and 
embryonic stem cells (ESC) [Payne et al. 2005, Smith et al. 2007, Schuldt et al. 2008]. 
However the rate of differentiation in vivo was very low. Instead, the major benefits were 
likely due to cardiac regeneration by endogenous cells that were activated by a paracrine 
mechanism through the donor cells. This was initially surprising because previously 
cardiomyocytes were believed to be terminally differentiated cells and hearts were 
thought to harbor few or no stem cells for regeneration. However there have been  recent 
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studies demonstrating that hearts have an endogenous cardiac stem cell population (CSC) 
that contributes to regeneration of damaged cardiac muscle.  This can occur by 
stimulating endogenous CSC in vivo or by ex-vivo expansion and transplantation of CSC.  
Thus, one mechanism by which exogenous cells may promote repair of damage to the 
heart is through  secretion of various factors that induce proliferation of endogenous cells 
in the heart including cardiac stem/progenitor cells and cardiomyocytes, or differentiation 
of stem/progenitor cells that contribute to repair or regeneration of the cardiac structure.  
 In addition to the effect of ADM on dystrophin-deficient cardiac muscle, this 
study has yielded interesting facts regarding disease-related changes in the heart of mdx 
and mdx/utrn-/- mouse models for DMD. For example mdx and mdx/utrn-/- mice have 
fewer DDR2 positive cardiac fibroblasts than hearts of age-matched wild type mice, 
which could affect stable extracellular matrix structure.  However, mdx mice had fewer 
DDR2 cells with increased collagen I expression, in contrast to mdx/utrn-/- mice which 
had also lower numbers of DDR2-positive cells but decreased collagen I expression. It 
may be DDR2 positive cells produce different amount of collagen I in mdx and mdx/utrn-
/- mice. Mdx and mdx/utrn-/- mice also have fewer proliferating cells in the heart than age 
matched wild type mice, which may indicate that  mdx and mdx/utrn-/- mice have less 
capacity  to maintain endogenous regeneration  than wild type mice.  This could be useful 
characteristics of these DMD mice models for future studies.   
 In summary ADM transplantation has a different effect on mdx and mdx/utrn-/- 
mice. ADM transplantation into the heart of mdx mice did not stimulate functional 
improvemen result in direct differentiation of donor cells to cardiomyocytes, or cause 
indirect effects. However in mdx/utrn-/- heart, ADM transplantation prevented 
  79 
development of dilated cardiomyopathy.  Our data suggest that this is due to both direct 
and indirect effects, including restored dystrophin. Therefore ADM delay development of 
dilated cardiomyopathy by transplantation prior to the onset of disease. However ADM 
do not improve function of dystrophic hearts when injected during advanced stages of 
dilated cardiomyopathy. 
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Figure 15. Scheme of ADM transplantation into mdx/utrn-/- mice prior to the onset of dilated 
cardiomyopathy 
 
 
Scheme of ADM transplantation to mdx/utrn-/- mice prior to the onset of dilated 
cardiomyopathy. Mdx/utrn-/- mice develop dilated cardiomyopathy with aging. At 5 
weeks of age when the mice are still relatively healthy, echocardiography was performed 
with mdx/utrn-/- mice. ADM were then transplanted, and second echocardiography was 
performed with the same mice 5 weeks after ADM transplantation, and then mice were 
euthanized. 
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Table 3. Primary antibodies for immunohistochemistry 
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Table 4.         Echocardiography comparison of before and after ADM transplantation in 
mdx/utrn-/- mice. WT/HBSS: wild type mice with saline injection, dKO/HBSS: mdx/utrn-
/- mice with saline injection and dKO/ADM: mdx/utrn-/- mice with ADM injection. IVSd: 
Interventricular septum at diastole, LVIDd: Left ventricular internal dimension at 
diastole, LVPWd: Left ventricular posterior wall at diastole, IVSs: Interventricular 
septum at systole, LVIDs: Left ventricular internal dimension at systole, LVPWs: Left 
ventricular posterior wall at systole, EDV: End-diastolic volume, ESV: End-systolic 
volume, EF: Ejection fraction, FS: Fractional shortening, SV: Stroke volume, HR: Heart 
rate. 
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Figure 16. Internal ventricular septum thickness (IVS) in mdx/utrn-/- mice 
 
 
Internal ventricular septum thickness (IVS) in mdx/utrn-/- mice. ADM injection 
prevented thinning of the septum. WT/HBSS: wild type mice with saline injection, 
dKO/HBSS: mdx/utrn-/- mice with saline injection and dKO/ADM: mdx/utrn-/- mice with 
ADM injection. *: p<0.05 
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Figure 17. Left ventricular internal dimension at diastole (LVIDd) in mdx/utrn-/- mice 
 
 
 
Left ventricular internal dimension at diastole (LVIDd) in mdx/utrn-/- mice. ADM 
injection prevented ventricular dilation. WT/HBSS: wild type mice with saline injection, 
dKO/HBSS: mdx/utrn-/- mice with saline injection and dKO/ADM: mdx/utrn-/- mice with 
ADM injection. *: p<0.05. 
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Figure 18. Left ventricular posterior wall thickness at diastole (LVPWd) in mdx/utrn-/- mice 
 
 
 
 
 
 
 
 
Left ventricular posterior wall thickness at diastole (LVPWd) in mdx/utrn-/- mice. 
ADM injection prevented the thinning of the left ventricular wall. WT/HBSS: wild type 
mice with saline injection, dKO/HBSS: mdx/utrn-/- mice with saline injection and 
dKO/ADM: mdx/utrn-/- mice with ADM injection. *: p<0.05. 
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Figure 19. End diastolic volume (EDV) in mdx/utrn-/- mice 
 
 
 
 
 
 
 
 
End diastolic volume (EDV) in mdx/utrn-/- mice.  ADM injection prevented the 
increase in EDV. WT/HBSS: wild type mice with saline injection, dKO/HBSS: mdx/utrn-
/- mice with saline injection and dKO/ADM:mdx/utrn-/- mice with ADM injection. *: 
p<0.05. 
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Figure 20. Ejection fraction (EF) in mdx/utrn-/- mice 
 
 
 
 
 
 
 
 
 
Ejection fraction (EF) in mdx/utrn-/- mice. WT/HBSS: wild type mice with saline 
injection. ADM injection did not affect to EF. dKO/HBSS: mdx/utrn-/- mice with saline 
injection and dKO/ADM:mdx/utrn-/- mice with ADM injection.  
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Figure 21. Fractional shortening (FS) in mdx/utrn-/- mice 
 
 
 
 
 
 
 
 
 
Fractional shortening (FS) in mdx/utrn-/- mice. WT/HBSS: wild type mice with 
saline injection, dKO/HBSS: mdx/utrn-/- mice with saline injection and 
dKO/ADM:mdx/utrn-/- mice with ADM injection.  
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Figure 22. Collagen I expression in hearts 
 
Collagen I expression in hearts. Wild type mice with saline injection (WT/HBSS) 
(A), mdx/utrn-/- with saline injection (dKO/HBSS) (B) and mdx/utrn-/- mice with ADM 
injection (dKO/ADM) (C). Collagen I: green, 20x magnification 
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Figure 23. Quantitative data of collagen I expression in hearts 
 
Quantitative data of collagen I expression in hearts of mdx/utrn-/- mice. Average 
collagen I positive areas of graph (A). WT/HBSS: wild type mice with saline injection, 
dKO/HBSS: mdx/utrn-/- mice with saline injection and dKO/ADM: mdx/utrn-/- mice with 
ADM injection. a, and b indicate a statistically significant difference in each group of 
mice. (P < 0.05). An example of collagen I positive area (arrow) (B, 20x magnification).  
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Figure 24. DDR2 expression in hearts 
DDR2 expression in hearts of mdx/utrn-/- mice. Wild type mice with saline 
injection (WT/HBSS) (A and B), mdx/utrn-/- mice with saline injection (dKO/HBSS) (C 
and D) and mdx/utrn-/- mice with ADM injection (dKO/ADM) (E and F). A, C and E: 
DDR2 (green), B, D and F: DDR2 (green) and DAPI (blue), 20x magnification 
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Figure 25. Quantitative data of DDR2 expressing cardiac fibroblasts in hearts 
 
 
Quantitative data of DDR2 expressing cardiac fibroblasts in hearts of mdx/utrn-/- 
mice. Average DDR2 positive cell number of graph (A), WT/HBSS: wild type mice with 
saline injection, dKO/HBSS: mdx/utrn-/- mice with saline injection and dKO/ADM: 
mdx/utrn-/- mice with ADM injection. . a, and b indicate a statistically significant 
difference in each group of mice. (P < 0.05). An example of DDR2 positive cells (arrow) 
(B, 20x magnification).  
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Figure 26. Ki-67 expression in hearts  
Ki-67 expression in hearts. Wild type mice with saline injection (WT/HBSS) (A 
and B), mdx/utrn-/- mice with saline injection (dKO/HBSS) (C and D) and mdx/utrn-/- 
mice with ADM injection (dKO/ADM) (E and F). A, C and E: Ki-67 (green), B, D and 
F:Ki-67 (green) and DAPI (blue), 20x magnification 
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Figure 27. Quantitative analysis of Ki-67expression in hearts 
 
 Quantitative data of Ki-67expression in hearts. Average Ki-67 positive cells of 
graph (A). WT/HBSS: wild type mice with saline injection, dKO/HBSS: mdx/utrn-/- mice 
with saline injection and dKO/ADM: mdx/utrn-/- mice with ADM injection. a, and b 
indicate a statistically significant difference in each group of mice. (P < 0.05). An 
example of Ki-67 positive cells (arrow) (B, 20x magnification).  
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Figure 28. CD31 expression in hearts 
 CD31 expression in hearts. Wild type mice with saline injection (WT/HBSS) (A 
and B), mdx/utrn-/- mice with saline injection (dKO/HBSS) (C and D) and mdx/utrn-/- 
mice with ADM injection (dKO/ADM) (E and F). A, C and E: CD31 (green), B, D and F: 
CD31 (green) and DAPI (blue), 20x magnification 
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Figure 29. Quantitative data of CD31 expression in hearts 
 
 
 Quantitative data of CD31 expression in hearts. Average CD31 positive cells of 
graph (A). WT/HBSS: wild type mice with saline injection, dKO/HBSS: mdx/utrn-/- mice 
with saline injection and dKO/ADM: mdx/utrn-/- mice with ADM injection. . a, and b 
indicate a statistically significant difference in each group of mice. (P < 0.05). An 
example of CD31 positive cells (arrow) (B, 20x magnification).  
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Figure 30. Connexin 43 expression in hearts 
 Connexin 43 expression in hearts. Wild type mice with saline injection 
(WT/HBSS) (A and B), mdx/utrn-/- mice with saline injection (dKO/HBSS) (C and D) 
and mdx/utrn-/- mice with ADM injection (dKO/ADM) (E and F). A, C and E: Connexin 
43 (green), B, D and F: Connexin 43 (green) and DAPI (blue), 20x magnification 
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Figure 31. Quantitative data of connexin 43 expression in hearts 
 
 
 Quantitative data of connexin 43 expression in hearts. Average connexin 43 
positive cells of graph (A). WT/HBSS: wild type mice with saline injection, dKO/HBSS: 
mdx/utrn-/- mice with saline injection and dKO/ADM: mdx/utrn-/- mice with ADM 
injection. a, and b indicate a statistically significant difference in each group of mice. (P < 
0.05). An example of connexin positive cells (arrow) (B, 20x magnification).  
 
 
 
  100 
Figure 32. Scheme of ADM transplantation to mdx mice  
 
 Scheme of ADM transplantation to mdx mice with dilated cardiomyopathy. Mdx 
mice develop dilated cardiomyopathy at later their life about 12 months old. At 14-16 
months old when the mice have developed dilated cardiomyopathy echocardiography was 
performed with mdx mice and then ADM was transplanted. Second echocardiography 
was performed with the same mice 10 weeks after ADM transplantation, and then mice 
were euthanizedwith dilated cardiomyopathy 
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Table 5.        Echocardiography in comparison of pre- and post- ADM transplantation in 
mdx mice. WT/HBSS: wild type mice with saline injection, Mdx/HBSS: mdx mice with 
saline injection and Mdx/ADM: mdx mice with ADM injection. IVSd: Interventricular 
septum at diastole, LVIDd: Left ventricular internal dimension at diastole, LVPWd: Left 
ventricular posterior wall at diastole, IVSs: Interventricular septum at systole, LVIDs: 
Left ventricular internal dimension at systole, LVPWs: Left ventricular posterior wall at 
systole, EDV: End-diastolic volume, ESV: End-systolic volume, EF: Ejection fraction, 
FS: Fractional shortening, SV: Stroke volume, HR: Heart rate. 
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Figure 33. Left ventricular internal dimension at diastole (LVIDd) in mdx mice 
 
 
 
 
 
 
 
 
 Left ventricular internal dimension at diastole (LVIDd) in mdx mice. WT/HBSS: 
wild type mice with saline injection, Mdx/HBSS: mdx mice with saline injection and 
Mdx/ADM: mdx mice with ADM injection. *: p<0.05. 
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Figure 34. Left ventricular posterior wall thickness at diastole (LVPWd) in mdx mice 
 
 
 
 
 
 
 
  
Left ventricular posterior wall thickness at diastole (LVPWd) in mdx mice. 
WT/HBSS: wild type mice with saline injection, Mdx/HBSS: mdx mice with saline 
injection and Mdx/ADM: mdx mice with ADM injection. *: p<0.05. 
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Figure 35. Ejection fraction (EF) in mdx mice 
 
 
 
 
 
 
 
 
 Ejection fraction (EF) in mdx mice. WT/HBSS: wild type mice with saline 
injection, Mdx/HBSS: mdx mice with saline injection and Mdx/ADM: mdx mice with 
ADM injection. *: p<0.05. 
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Figure 36. Fractional shortening (FS) in mdx mice 
 
 
 
 
 
 
 
 
 Fractional shortening (FS) in mdx mice. WT/HBSS: wild type mice with saline 
injection, Mdx/HBSS: mdx mice with saline injection and Mdx/ADM: mdx mice with 
ADM injection. *: p<0.05. 
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Figure 37. End diastolic volume (EDV) in mdx mice 
 
 
 
 
 
 
 
 
 End diastolic volume (EDV) in mdx mice. WT/HBSS: wild type mice with saline 
injection, Mdx/HBSS: mdx mice with saline injection and Mdx/ADM: mdx mice with 
ADM injection. *: p<0.05. 
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Figure 38. Collagen I expression in hearts 
 
 
  
 
Collagen I expression in hearts. Wild type mice with saline injection (WT/HBSS) 
(A), mdx mice with saline injection (Mdx/HBSS) (B) and mdx mice with ADM injection 
(Mdx/ADM) (C). Collagen I: green, 20x magnification 
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Figure 39. Quantitative data of collagen I expression in hearts 
 
 Quantitative data of collagen I expression in hearts. Average collagen I positive 
areas of graph (A). WT/HBSS: wild type mice with saline injection, Mdx/HBSS: mdx 
mice with saline injection and Mdx/ADM: mdx mice with ADM injection. a, and b 
indicate a statistically significant difference in each group of mice. (P < 0.05). An 
example of collagen I positive area (arrow) (B, 20x magnification). 
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Figure 40. DDR2 expression in hearts 
 DDR2 expression in hearts. Wild type mice with saline injection (WT/HBSS) (A 
and B), mdx mice with saline injection (Mdx/HBSS) (C and D) and mdx mice with ADM 
injection (Mdx/ADM) (E and F). A, C and E: DDR2 (green), B, D and F: DDR2 (green) 
and DAPI (blue), 20x magnification 
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Figure 41. Quantitative data of DDR2 expressing in hearts 
 
 
 Quantitative data of DDR2 expressing cardiac fibroblasts in hearts. Average 
DDR2 positive cell number of graph (A), WT/HBSS: wild type mice with saline 
injection, Mdx/HBSS: mdx mice with saline injection and Mdx/ADM: mdx mice with 
ADM injection. a, and b indicate a statistically significant difference in each group of 
mice. (P < 0.05). An example of DDR2 positive cells (arrow) (B, 20x magnification).  
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Figure 42. Ki-67 expression in hearts 
Ki-67 expression in hearts. Wild type mice with saline injection (WT/HBSS) (A 
and B), mdx mice with saline injection (Mdx/HBSS) (C and D) and mdx mice with ADM 
injection (Mdx/ADM) (E and F). A, C and E: Ki-67 (green), B, D and F: Ki-67 (green) 
and DAPI (blue), 20x magnification 
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Figure 43. Quantitative analysis of Ki-67 expression in hearts 
 
 
 Quantitative data of Ki-67 expression in hearts. Average Ki-67 positive cell 
number of graph (A), WT/HBSS: wild type mice with saline injection, Mdx/HBSS: mdx 
mice with saline injection and Mdx/ADM: mdx mice with ADM injection. a, and b 
indicate a statistically significant difference in each group of mice. (P < 0.05). An 
example of Ki-67 positive cells (arrow) (B, 20x magnification).  
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Figure 44. CD31 expression in hearts 
CD31 expression in hearts. Wild type mice with saline injection (WT/HBSS) (A 
and B), mdx mice with saline injection (Mdx/HBSS) (C and D) and mdx mice with ADM 
injection (Mdx/ADM) (E and F). A, C and E: CD31 (green), B, D and F: CD31 (green) 
and DAPI (blue), 20x magnification 
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Figure 45. Quantitative analysis of CD31 expression in hearts 
 
 Quantitative data of CD31 expression in hearts. Average CD31 positive cell 
number of graph (A), WT/HBSS: wild type mice with saline injection, Mdx/HBSS: mdx 
mice with saline injection and Mdx/ADM: mdx mice with ADM injection. a, and b 
indicate a statistically significant difference in each group of mice. (P < 0.05). An 
example of CD31 positive cells (arrow) (B,20x magnification).  
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Figure 46. Connexin 43 expression in hearts 
 Connexin 43 expression in hearts. Wild type mice with saline injection 
(WT/HBSS) (A and B), mdx mice with saline injection (Mdx/HBSS) (C and D) and mdx 
mice with ADM injection (Mdx/ADM) (E and F). A, C and E: Connexin 43 (green), B, D 
and F: Connexin 43 (green) and DAPI (blue), 20x magnification 
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Figure 47. Quantitative analysis of connexin 43 expression in hearts 
 
 
Quantitative data of connexin 43 expression in hearts. Average connexin 43 
positive cell number of graph (A), WT/HBSS: wild type mice with saline injection, 
Mdx/HBSS: mdx mice with saline injection and Mdx/ADM: mdx mice with ADM 
injection. a, and b indicate a statistically significant difference in each group of mice. (P < 
0.05). An example of connexin positive cells (arrow) (B,20x magnification).  
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Figure 48. Restored dytrophin expression in mdx/utrn-/- mice with ADM 
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Figure 48. Restored dytrophin expression. Wild type control mice with saline 
injection (A and B), mdx/utrn-/- mice with ADM injection (C-F), mdx mice with ADM 
injection (G and H). A, C, E and G: Dystrophin (green), B, D, F and H: Dystrophin 
(green) and DAPI (blue). Mdx/utrn-/- mice with ADM injection showed weaker 
dystrophin positive signal (C and D) and stronger dystrophin positive signals (E and F). 
Mdx mice with ADM injection showed no restored dystrophin expression (G and H). 20x 
magnification. 
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Figure 49. Restored dytrophin expression in mdx/utrn-/- mice with ADM 
                           A     B      C     D      E      F      G      H      I      J      K      L      M   
 
 
 
 
 No dystrophin detected by western blot in mdx/utrn-/- mice with ADM injection. 
A, B, C and D: wild type mice with HBSS injection, E, F, G and H: mdx/utrn-/- mice with 
HBSS injection, I, J, K, L and M: mdx/utrn-/- mice with ADM injection. Dystrophin 
protein is Dp427 kDa and GAPDH is loading control.  
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Chapter V 
Summary and conclusion 
  
 The focus of this dissertation was to evaluate the capacity of ADM multipotent adult stem 
cells for the treatment of DCM in DMD. The absence of dystrophin in DMD causes skeletal and 
cardiac muscle defects [Hoffman et al. 1987, Oldfors et al. 1994]. There have been many studies 
to improve skeletal muscle defects including respiratory system that brought prolonged life to 
patients with DMD [Eagle et al. 2007]. Unfortunately, extended lifespan leads to worsening of 
cardiac muscle condition [Danialou et al. 2001, Fiona et al. 2005, Townsand et al. 2008 and 
Kamogawa et al. 2009]. There are increasing numbers of studies and clinical trials to understand 
cardiac involvement [Townsend et al. 2010, Spurney et al. 2011] and how it might be addressed, 
but there is still no long-term cure for cardiac pathology in DMD [Das et al. 2009, Bostick et al. 
2009].  
For the treatment of DCM in DMD it is important to replace damaged/dead 
cardiomyocytes to prevent further cardiac dysfunction. Stem cell therapy may be a good strategy 
for treating cardiac involvement in DMD because of their ability to proliferate and differentiate 
to cardiomyocytes for regeneration. Multipotent ADM differentiate skeletal muscle fibers and 
restore both healthy muscle fibers and dystrophin in mdx/utrn-/- mice [Berry et al. 2007]. Here I 
demonstrated that ADM may be useful for therapy for not only skeletal but also cardiac muscle 
in DMD.  Three points were addressed in this study to achieve this conclusion: 1) 
characterization of DCM in the phenotypic animal model for DMD to establish its relevance for 
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use in studies with ADM treatment for DCM in DMD, 2) differentiation capacity of ADM into 
cardiomyocytes, and 3) the effect(s) of ADM transplantation in dystrophic hearts.  
There are two transgenic mice which have been used as animal models for DMD. Mdx 
mice have a single dystrophin mutation identical to that of many DMD patients that makes them 
genotypic animal model for DMD. Despite this, mdx mice have mild skeletal muscle defect with 
relatively normal lifespan unlike DMD patients [Bulfield et al. 1984]. Mdx/utnr-/- mice have 
dystrophin and utrophin mutations with severe, progressive skeletal muscle defects similar to 
DMD patients [Grady et al. 1997] and are therefore a good phenotypic model for DMD.   Mdx 
mice develop DCM in close to the end of their lifespan [Quinlan et al. 2004] However, mdx/utrn-
/- mice had not previously been reported to develop DCM. The mdx/utrn-/- mice were examined 
to determine whether they develop DCM like patients with DMD [Chun et al. 2012]. 
Echocardiography was used to  demonstrate that mdx/utrn-/- mice gradually develop DCM. At 5 
weeks of age  no decreased in cardiac function was detected in mdx/utrn-/- mice. At the age of 10 
weeks thinning heart walls and an enlarged left ventricular chamber were present, and at 15 
weeks of age decreased EF, FS and EDV with excessive fibrosis formation was detected. In 
addition mdx/utrn-/- mice develop DCM with a similar progression and time frame to DMD 
patients. These data, collectively, confirm that mdx/utrn-/- mice develop DCM like DMD patients, 
and are a good disease model for pre-clinical studies to treat DCM in DMD. 
 As stem cell therapy for cardiomyopathy in DMD, ADM must have the capacity to 
differentiate into cardiomyocytes and restore dystrophin. Here I have reported that ADM were 
induced to differentiate into cardiomyocytes, using one of   three different supplements in vitro. 
97.8% of ADM in N2B27 differentiation medium exhibited a change in morphology similar to 
that of cardiomyocytes, and 60% of them expressed cTm protein. ADM also expressed the 
  123 
cardiac markers Nkx2.5, cTnI, cTm and α-actinin, as well as connexin 43, expressed at 14 days 
in cardiomyocytes. After transplantation to hearts DiI-labeled ADM were colocalized with the 
cardiac marker cTn. Moreover restored dystrophin was detected in the heart of mdx mice after 
ADM transplantation.  As a result, we concluded that ADM likely differentiate into 
cardiomyocytes and even restore dystrophin in the heart of mdx mice.  
The effect of ADM transplantation on DCM in DMD was tested in two different 
experimental groups.  First, 14~16 month old mdx mice were injected with ADM following 
development of severe DCM to study whether ADM alleviated DCM in DMD. Using 
echocardiography no functional improvement was detected after ADM transplantation.  Likewise, 
no decrease in pathology was detected by immunohistochemistry, and no restored dystrophin 
was detected. Next, ADM were transplanted into the hearts of 5 week old mdx/utrn-/- mice, prior 
to the development of DCM to determine whether ADM prevent or delay onset of DCM. 
Echocardiography was used to determine that mdx/utrn-/- mice do not exhibit ventricular dilation 
and in fact have similar heart function to age matched wild type mice. There were also 
endogenous regenerative  activities in the heart of mdx/utrn-/- mice injected with ADM. include  
increased CD31 expression, indicating  new vessel formation, and a trend towards increased 
numbers of Ki-67 positive cells (p<0.07), indicating that there was in increase in  proliferating 
cells in cardiac muscle injected with ADM. Interestingly restored dystrophin was detected in the 
heart of mdx/utrn-/- mice by immunohistochemistry, but not  by western blot, potentially because  
the amount of restored dystrophin may be  too small to be detected by western blot. Altogether, 
these data indicate that ADM transplantation prior to the onset of cardiac pathology and 
dysfunction prevented or delayed development of DCM in mdx/utrn-/- mice but transplantation 
after development of pathology and dysfunction did not improve existing DCM in mdx mice. 
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Thus, I conclude that ADM could be a good source of stem cell for therapeutic purposes that 
prevent/delay development of DCM in DMD. 
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